EP4100052A2 - Vaccins à domaine arnm anti sars-cov-2 - Google Patents

Vaccins à domaine arnm anti sars-cov-2

Info

Publication number
EP4100052A2
EP4100052A2 EP21709270.9A EP21709270A EP4100052A2 EP 4100052 A2 EP4100052 A2 EP 4100052A2 EP 21709270 A EP21709270 A EP 21709270A EP 4100052 A2 EP4100052 A2 EP 4100052A2
Authority
EP
European Patent Office
Prior art keywords
mrna
seq
mol
amino acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21709270.9A
Other languages
German (de)
English (en)
Inventor
Guillaume Stewart-Jones
Andrea Carfi
Sayda Mahgoub Elbashir
Mihir METKAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of EP4100052A2 publication Critical patent/EP4100052A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Definitions

  • Human coronaviruses are highly contagious enveloped, positive single-stranded RNA viruses of the Coronaviridae family. Two sub-families of Coronaviridae are known to cause human disease. The most important being the ⁇ -coronaviruses (betacoronaviruses). The b- coronaviruses are common etiological agents of mild to moderate upper respiratory tract infections. Outbreaks of novel coronavirus infections such as the infections caused by a coronavirus initially identified from the Chinese city of Wuhan in December 2019, however, have been associated with a high mortality rate death toll.
  • SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
  • 2019-nCoV coronavirus 2
  • WHO World Health Organization
  • COVID-19 Coronavirus Disease 2019
  • the first genome sequence of a SARS-CoV-2 isolate was released by investigators from the Chinese CDC in Beijing on January 10, 2020 at Virological, a UK-based discussion fomm for analysis and interpretation of vims molecular evolution and epidemiology. The sequence was then deposited in GenBank on January 12, 2020, having Genbank Accession number MN908947.1.
  • compositions e.g., vaccines
  • mRNA molecules that encode(s) highly immunogenic antigen(s) capable of eliciting potent neutralizing antibody responses against SARS-CoV-2 antigens.
  • S SARS-CoV-2 coronavirus spike
  • the envelope S proteins of known betacoronaviruses determine the virus host tropism and entry into host cells and are critical for SARS-CoV-2 infection.
  • the organization of the S protein is similar among betacoronavimses, such as SARS-CoV-2, SARS-CoV, MERS-CoV, HKUl-CoV, MHV-CoV and NL63-CoV, including two subunits, SI and S2, which mediate attachment and membrane fusion, respectively.
  • the S 1 subunit includes an N terminal domain (NTD) and a receptor binding domain (RBD).
  • subunit antigens focuses the immune response to specific subunits with minimal stimulation of memory B and T cells specific to other domains of the antigen that are shared with other related viruses.
  • Data provided herein demonstrates that administration of mRNA encoding membrane bound or soluble SARS-CoV-2 SI subunit antigen generated antibody titers to each of SARS-CoV-2 RBD antigen, NTD antigen, wildtype full-length S protein, and S protein having double proline mutations to stabilize the prefusion conformation.
  • a two-dose regimen i.e., including a booster dose
  • the induced titers were highest when measured against the double proline stabilized version of the S protein even though the double proline mutation is not found in the S 1 subunit (the double proline mutation occurs in S2, and S2 was not present in the immunogen tested).
  • both the NTD and RBD are known to be sites for binding of antibodies that neutralize virus activity.
  • RBD in the case of SARS-CoV-2 is the receptor binding site of the spike protein which binds the angiotensin-converting enzyme 2 (ACE2).
  • ACE2 angiotensin-converting enzyme 2
  • the NTD the function of which is not thoroughly understood, seems to have a role in binding sugar moieties and in facilitating the conformational transition of the spike protein from prefusion to a post fusion conformation.
  • both the NTD and RBD domains induce high binding antibody and neutralizing antibody titers as shown herein.
  • the data provided in some embodiments herein show that while sera from the administration of mRNA encoding a membrane bound RBD antigen (RBD- TM) or a membrane bound NTD antigen (NTD-TM) showed immunogenicity to the SARS-CoV- 2 S1/S2 spike protein, the 50:50 combination of the two mRNAs (and thus the two antigens) generated unexpectedly high, synergistic, neutralizing antibody titers to the SARS-CoV-2 S1/S2 spike protein.
  • RBD- TM membrane bound RBD antigen
  • NTD-TM membrane bound NTD antigen
  • compositions comprising an mRNA encoding a functional domain of a SARS-CoV-2 S protein capable of inducing an immune response, such as a neutralizing antibody response, to a SARS-CoV-2.
  • the mRNA is formulated in a lipid nanoparticle.
  • an mRNA comprising an open reading frame (ORF) that encodes at least two domains of a SARS-CoV-2 Spike protein, and less than the full length spike protein.
  • a spike protein that is less than the full length spike protein is one or more domains and/or subunits of the spike protein having at least one amino acid less than the full length spike protein or a fusion protein having one or more domains linked together in an non-natural order or sequence.
  • one of the two domains is an N-terminal domain (NTD) of a SARS-CoV-2 Spike protein.
  • one of the two domains is a receptor binding domain (RBD) of a SARS-CoV-2 Spike protein.
  • the ORF encodes a transmembrane domain (TD) linked to the NTD and/or RBD.
  • the TD is an influenza hemagglutinin transmembrane domain.
  • the ORF comprises NTD - RBD - TM.
  • the at least two domains are linked through a cleavable or non-cleavable linker.
  • the non-cleavable linker is a glycine-serine (GS) linker.
  • the GS linker 4-15 amino acids.
  • the linker is a pan HLA DR-binding epitope (PADRE).
  • the ORF encodes a signal peptide.
  • the signal peptide is linked to the NTD. In some embodiments the signal peptide is linked to the RBD. In some embodiments the signal peptide is heterologous to SARS-CoV-2. In some embodiments the at least two domains are soluble. In some embodiments the ORF encodes a trafficking signal domain. In some embodiments the trafficking signal domain is a macrophage marker. In some embodiments the macrophage marker CD86 and/or CD1 lb. In some embodiments the trafficking signal domain is a VSV-G cytosolic tail (VSVGct). In some embodiments one of the two domains is a first repetitive heptapeptide: HPPHCPC (HR1) of a SARS-CoV-2 Spike protein.
  • one of the two domains is a second repetitive heptapeptide: HPPHCPC (HR2) of a SARS-CoV-2 Spike protein.
  • the ORF encodes a transmembrane domain (TD) linked to the HR1 and/or HR2.
  • the TD is an influenza hemagglutinin transmembrane domain.
  • the ORF encodes a fusion peptide (FP).
  • the ORF encodes a CT tail.
  • an mRNA comprising an open reading frame (ORF) that encodes a receptor binding domain (RBD) of a SARS-CoV-2 Spike protein is provided.
  • RBD receptor binding domain
  • the RBD is soluble.
  • the RBD is linked to a transmembrane domain, optionally an influenza hemagglutinin transmembrane domain.
  • FIG. 1 Schematic representation of wild-type and 2P spike protein antigens encoded by mRNAs of the invention; signal peptide (SP), no fill, N-terminal domain (NTD), dotted; receptor-binding domain (RBD), downward diagonal stripes; subdomain 1 (SD1), horizontal stripes; subdomain 2 (SD2), wave; fusion peptide (FP), upward diagonal stripes; heptad repeat 1 (HR1) weave; heptad repeat 2 (HR2) diagonal brick; (TM), vertical stripes; and cytoplasmic tail (CT), brick.
  • SP signal peptide
  • NTD N-terminal domain
  • RBD receptor-binding domain
  • FP receptor-binding domain
  • HR1 subdomain 1
  • SD2 subdomain 2
  • FP fusion peptide
  • HR1 heptad repeat 1
  • HR2 heptad repeat 2
  • TM cytoplasmic tail
  • FIG. 2 shows examplary linear designs of the antigens encoded by the mRNAs described in Examples 1-3.
  • FIG. 3 shows sequence alignments of the antigens depicted in FIG. 2.
  • FIG. 4 shows examplary linear designs of the antigens encoded by the mRNAs described in Examples 4-6.
  • FIG. 5 shows sequence alignments of various SI subunit antigens described herein.
  • FIG. 6 shows examplary linear designs of the antigens encoded by the mRNAs described in Examples 7 and 8.
  • FIG. 7 shows correlations of neutralization and ELISA titers.
  • FIGs. 8A-8C show serum IgGl and IgG2a Titers at Day 36 following a Day 1 prime and Day 21 boost dose in mice with mRNA encoding NTD-RBD-TM in an LNP.
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerging respiratory virus with high morbidity and mortality.
  • SARS-CoV-2 has rapidly spread around the world compared with SARS-CoV, which appeared in 2002, and Middle East respiratory syndrome coronavirus (MERS-CoV), which emerged in 2012.
  • the World Health Organization (WHO) reports that, as of July 6, 2020, the current outbreak of COVID-19 has almost 11.5 million confirmed cases worldwide with more than 530,000 deaths. New cases of COVID-19 infection are on the rise and are still increasing rapidly. It is thus crucial that a variety of safe and effective vaccines and drugs be developed to prevent and treat COVID-19 and reduce the serious impact that COVID-19 is having across the world.
  • Vaccines and drugs made using a variety of modalities, and vaccines having improved safety and efficacy, are imperative. Their remains a need to accelerate the advanced design and development of vaccines and therapeutic drugs against coronavirus disease 2019 (COVID-19).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2 b-coronaviruses
  • Spike protein A key protein on the surface of coronavirus is the Spike protein.
  • a large variety of mRNA constructs have been designed and are disclosed herein.
  • mRNA encoding Spike antigen subunits and domains thereof are capable of inducing a strong immune response against SARS-CoV-2, thus producing effective and potent mRNA vaccines.
  • Administration of the mRNA encoding various Spike protein antigens, in particular, Spike protein subunit and domain antigens results in delivery of the mRNA to immune tissues and cells of the immune system where it is rapidly translated into proteins antigens.
  • immune cells for example, B cells and T cells
  • B cells and T cells are then able to recognize and mount and immune response develop an immune response against the encoded protein and ultimately create a long -lasting protective response against the coronavirus.
  • Low immunogenicity a drawback in protein vaccine development due to poor presentation to the immune system or incorrect folding of the antigens, is avoided through the use of the highly effective mRNA vaccines encoding spike protein, subunits and domains thereof disclosed herein.
  • compositions that elicit potent neutralizing antibodies against coronavirus antigens.
  • a composition includes mRNA encoding at least one (e.g., one, two, or more) coronavirus antigen, such as a SARS-CoV-2 antigen.
  • the mRNA encodes a spike protein domain, such as a receptor binding domain (RBD), an N-terminal domain (NTD), or a combination of an RBD and NTD.
  • RBD receptor binding domain
  • NTD N-terminal domain
  • mRNA messenger ribonucleic acid
  • RBD receptor binding domain
  • SARS-CoV-2 Spike protein a protein transmembrane domain
  • the protein transmembrane domain is an influenza hemagglutinin transmembrane domain.
  • the fusion protein comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 77.
  • the fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77.
  • the fusion protein comprises the amino acid sequence of SEQ ID NO: 77.
  • the open reading frame comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 76.
  • the wherein the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76.
  • the open reading frame comprises the nucleotide sequence of SEQ ID NO: 76.
  • mRNA messenger ribonucleic acid
  • mRNA messenger ribonucleic acid
  • the transmembrane domain is an influenza hemagglutinin transmembrane domain.
  • the fusion protein comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 47.
  • the fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47.
  • the fusion protein comprises the amino acid sequence of SEQ ID NO: 47.
  • the open reading frame comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 46. In some embodiments, the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46.
  • the open reading frame comprises the nucleotide sequence of SEQ ID NO: 46.
  • mRNA messenger ribonucleic acid
  • the fusion protein further comprises a transmembrane domain.
  • the fusion protein comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 92.
  • the fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 92.
  • the fusion protein comprises the amino acid sequence of SEQ ID NO: 92.
  • the open reading frame comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 91.
  • the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 91.
  • the open reading frame comprises the nucleotide sequence of SEQ ID NO: 91.
  • the mRNA further comprises a 5' untranslated region (UTR), optionally comprising the nucleotide sequence of SEQ ID NO: 131 or 2.
  • UTR 5' untranslated region
  • the mRNA further comprises a 3' untranslated region (UTR), optionally comprising the nucleotide sequence of SEQ ID NO: 132 or 4.
  • UTR 3' untranslated region
  • the mRNA further comprises a 5' cap, optionally 7mG(5’)ppp(5’)NlmpNp.
  • the mRNA further comprises a polyA tail, optionally having a length of about 100 nucleotides.
  • the mRNA comprises a chemical modification, optionally 1- methylpseudouridine.
  • compositions comprising at least two of the mRNA of any one of the preceding paragraphs.
  • compositions comprising: (a) a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a fusion protein comprising a receptor binding domain (RBD) of a SARS-CoV-2 Spike protein and a protein transmembrane domain; and (b) an mRNA comprising an open reading frame encoding a fusion protein comprising an amino (N)-terminal domain of a SARS-CoV-2 Spike protein and a transmembrane domain.
  • the ratio of the mRNA of (a) to the mRNA of (b) is about 1:1, e.g., 1:2, 1:3, 21:, or 3:1.
  • At least 50% of the mRNA of a composition is the mRNA of (a).
  • at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the mRNA of a composition is the mRNA of (a).
  • at least 50% of the mRNA of a composition is the mRNA of (b).
  • at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the mRNA of a composition is the mRNA of (b).
  • the protein transmembrane domain is an influenza hemagglutinin transmembrane domain.
  • the fusion protein of (a) comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 77.
  • the fusion protein of (a) comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77.
  • the fusion protein of (a) comprises the amino acid sequence of SEQ ID NO: 77.
  • the open reading frame of (a) comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 76.
  • the open reading frame of (a) comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76.
  • the open reading frame of (a) comprises the nucleotide sequence of SEQ ID NO: 76.
  • the fusion protein of (b) comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 47. In some embodiments, the fusion protein of (b) comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47.
  • the fusion protein of (b) comprises the amino acid sequence of SEQ ID NO: 47.
  • the open reading frame of (b) comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 46.
  • the open reading frame of (b) comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46.
  • the open reading frame of (b) comprises the nucleotide sequence of SEQ ID NO: 46.
  • the mRNA is formulated in a lipid nanoparticle.
  • the composition further comprises a lipid nanoparticle.
  • the mRNA of (a) is formulated in a lipid nanoparticle, and the mRNA of (b) is formulated in a lipid nanoparticle.
  • the lipid nanoparticle comprises a cationic lipid.
  • the lipid nanoparticle further comprises a neutral lipid.
  • the lipid nanoparticle further comprises a sterol.
  • the lipid nanoparticle further comprises a polyethylene glycol (PEG)-modified lipid.
  • PEG polyethylene glycol
  • the lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.
  • the ionizable cationic lipid is heptadecan-9-yl 8 ((2 hydroxyethyl)(6 oxo 6-(undecyloxy)hexyl)amino)octanoate (Compound 1).
  • the neutral lipid is 1,2 distearoyl-sn-glycero-3-phosphocholine (DSPC).
  • the sterol is cholesterol
  • the PEG-modified lipid is 1,2 dimyristoyl-sn-glycerol, methoxypolyethyleneglycol (PEG2000 DMG).
  • the lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid, 5-25 mol% neutral lipid, 25-55 mol% sterol, and 0.5-15 mol% PEG-modified lipid.
  • the lipid nanoparticle comprises: 47 mol% ionizable cationic lipid; 11.5 mol% neutral lipid; 38.5 mol% sterol; and 3.0 mol% PEG-modified lipid; 48 mol% ionizable cationic lipid; 11 mol% neutral lipid; 38.5 mol% sterol; and 2.5 mol% PEG-modified lipid; 49 mol% ionizable cationic lipid; 10.5 mol% neutral lipid; 38.5 mol% sterol; and 2.0 mol% PEG-modified lipid; 50 mol% ionizable cationic lipid; 10 mol% neutral lipid; 38.5 mol% sterol; and 1.5 mol% PEG-modified lipid; or 51 mol% ionizable cationic lipid; 9.5 mol% neutral lipid;
  • the lipid nanoparticle comprises: 47 mol% Compound 1; 11.5 mol% DSPC; 38.5 mol% cholesterol; and 3.0 mol% PEG2000 DMG; 48 mol% Compound 1; 11 mol% DSPC; 38.5 mol% cholesterol; and 2.5 mol% PEG2000 DMG; 49 mol% Compound 1;
  • Further aspects of the present disclosure provide a method comprising administering to a subject the mRNA or the composition of any one of the preceding claims in an amount effective to induce in the subject a neutralizing antibody response against SARS-CoV-2.
  • aspects of the present disclosure provide a method comprising administering to a subject the mRNA or the composition of any one of the preceding claims in an amount effective to induce in the subject and a T cell immune response against SARS-CoV-2.
  • mRNA messenger ribonucleic acid
  • ORF open reading frame
  • a coronavirus antigen capable of inducing an immune response, such as a neutralizing antibody response
  • the antigen comprises a protein fragment or a functional protein domain of a SARS-CoV-2
  • the RNA is formulated in a lipid nanoparticle.
  • the antigen is a functional protein domain.
  • the protein domain is an N-terminal domain (NTD) of a SARS- CoV-2 Spike protein.
  • the NTD is linked to a transmembrane domain, optionally an influenza hemagglutinin transmembrane domain.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 47.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 46.
  • the protein domain is a receptor binding domain (RBD) of a SARS-CoV-2 Spike protein.
  • the RBD is soluble.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 62, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 62.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 61, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 61.
  • the RBD is linked to a transmembrane domain, optionally an influenza hemagglutinin transmembrane domain.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 77.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NOs: 76.
  • the NTD is linked to an RBD of a SARS-CoV-2 Spike protein to form an NTD-RBD fusion protein.
  • the NTD-RBD fusion is linked to a transmembrane domain (TM), optionally an influenza hemagglutinin transmembrane domain, to form an NTD-RBD-TM protein.
  • TM transmembrane domain
  • influenza influenza hemagglutinin transmembrane domain
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 92, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 92.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 91, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 91.
  • the NTD-RBD fusion comprises a C-terminal truncation.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 107, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 107.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 106, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 106.
  • the NTD and/or RBD includes an extended region.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 59, 86, 89, 116, 119, or 122, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 59, 86, 89, 116, 119, or 122.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 58, 85, 88, 115, 118, or 121, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 58, 85, 88, 115, 118, or 121.
  • the protein domain is an SI subunit domain of a SARS-CoV-2 Spike protein.
  • the S 1 subunit is soluble.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 5, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 5.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 3, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 3.
  • the S 1 subunit is linked to a transmembrane domain, optionally an influenza hemagglutinin transmembrane domain.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 17, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 17.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 16, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 16.
  • the S 1 subunit has been modified to remove an RBD or a portion of an RBD of S protein.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 20, 23, 26, 29, 32 or 35, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 20, 23, 26, 29, 32, or 35.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 19, 22, 25, 28, 41, or 34, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 19, 22, 25, 28, 31, or 34.
  • the SI subunit is linked to an S2 subunit of an S protein.
  • the S2 subunit is from a SARS-CoV-2 S protein.
  • the SI subunit is from an HKU1 S protein.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 38, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 38.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 37, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 37.
  • the S 1 subunit is from an OC43 S protein.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 41, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 41.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 40, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 40.
  • the antigen further comprises a scaffold domain, optionally selected from ferritin, lumazine synthetase and a foldon.
  • the scaffold domain is ferritin.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 8 or 65, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 8 or 65.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 7 or 64, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 7 or 64.
  • the scaffold domain is lumazine synthetase.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 11, 14, 68, or 71, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 11, 14, 68, or 71.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 10, 13, 67, or 70, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 10, 13, 67, or 70.
  • the scaffold domain is a foldon.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 44, 50, 74, 80, 83, 101, 104 or 113, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 44, 50, 74, 80, 83, 101, 104 or 113.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 43, 49, 73, 79, 82, 100, 103, or 112, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 43, 49, 73, 79, 82, 100, 103, or 112.
  • the antigen further comprises a trafficking signal, optionally selected from macrophage markers, optionally CD86, CD11B and/or VSVGct.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 95, 98, or 110, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 95, 98, or 110.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 94, 97, or 109, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 94, 97, or 109.
  • the mRNA is formulated in a lipid nanoparticle.
  • the lipid nanoparticle comprises a cationic lipid, optionally an ionizable cationic lipid, a neutral lipid, a sterol, and/or a polyethylene glycol (PEG) -modified lipid.
  • a cationic lipid optionally an ionizable cationic lipid, a neutral lipid, a sterol, and/or a polyethylene glycol (PEG) -modified lipid.
  • PEG polyethylene glycol
  • the lipid nanoparticle comprises 40-50 mol% ionizable lipid, optionally 45-50 mol%, for example, 45-46 mol%, 46-47 mol%, 47-48 mol%, 48-49 mol%, or 49-50 mol% for example about 45 mol%, 45.5 mol%, 46 mol%, 46.5 mol%, 47 mol%, 47.5 mol%, 48 mol%, 48.5 mol%, 49 mol%, or 49.5 mol%.
  • the lipid nanoparticle comprises 30-45 mol% sterol, optionally 35-40 mol%, for example, 30-31 mol%, 31-32 mol%, 32-33 mol%, 33-34 mol%, 35-35 mol%, 35-36 mol%, 36-37 mol%, 38-38 mol%, 38-39 mol%, or 39-40 mol%.
  • the lipid nanoparticle comprises 5-15 mol% helper lipid, optionally 10-12 mol%, for example, 5-6 mol%, 6-7 mol%, 7- 8 mol%, 8-9 mol%, 9-10 mol%, 10-11 mol%, 11-12 mol%, 12-13 mol%, 13-14 mol%, or 14-15 mol%.
  • the lipid nanoparticle comprises 1-5% PEG lipid, optionally 1-3 mol%, for example 1.5 to 2.5 mol%, 1-2 mol%, 2-3 mol%, 3-4 mol%, or 4-5 mol%.
  • the ionizable cationic lipid is heptadecan-9-yl 8 ((2 hydroxyethyl)(6 oxo 6-(undecyloxy)hexyl)amino)octanoate (Compound 1), the neutral lipid is
  • I,2 distearoyl-sn-glycero-3-phosphocholine DSPC
  • the sterol is cholesterol
  • the PEG- modified lipid is 1,2 dimyristoyl-sn-glycerol, methoxypolyethyleneglycol (PEG2000 DMG).
  • the lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid, 5-25 mol% neutral lipid, 25-55 mol% sterol, and 0.5-15 mol% PEG-modified lipid.
  • the lipid nanoparticle comprises: 47 mol% ionizable cationic lipid
  • the lipid nanoparticle comprises: 47 mol% Compound 1; 11.5 mol% DSPC; 38.5 mol% cholesterol; and 3.0 mol% PEG2000 DMG; 48 mol% Compound 1; 11 mol% DSPC; 38.5 mol% cholesterol; and 2.5 mol% PEG2000 DMG; 49 mol Compound 1;
  • SARS-CoV-2 The genome of SARS-CoV-2 is a single-stranded positive- sense RNA (+ssRNA) with the size of 29.8-30 kb encoding about 9860 amino acids (Chan et al.2000, supra; Kim et al. 2020 Cell, May 14; 181(4):914-921.el0.).
  • SARS-CoV-2 is a polycistronic mRNA with 5'-cap and 3'- poly-A tail.
  • the SARS-CoV-2 genome is organized into specific genes encoding structural proteins and nonstructural proteins (Nsps).
  • the order of the structural proteins in the genome is 5'-replicase (open reading frame (ORF)l/ab)-structural proteins [Spike (S)-Envelope (E)- Membrane (M)-Nucleocapsid (N)]-3'.
  • ORF open reading frame
  • the genome of coronaviruses includes a variable number of open reading frames that encode accessory proteins, nonstructural proteins, and structural proteins (Song et al. 2019 Viruses; ll(l):p. 59). Most of the antigenic peptides are located in the structural proteins (Cui et al. 2019 Nat. Rev. Microbiol.; 17(3): 181-192).
  • Spike surface glycoprotein (S), a small envelope protein (E), matrix protein (M), and nucleocapsid protein (N) are four main structural proteins. Since S-protein contributes to cell tropism it is capable of inducing neutralizing antibodies (NAb) and protective immunity, it can be considered one of the most important targets in coronavirus vaccine development among all other structural proteins. Moreover, amino acid sequence analysis has shown that S-protein contains conserved regions among the coronaviruses, which may be the basis for universal vaccine development
  • compositions of the invention feature nucleic acids, in particular, mRNAs, designed to encode an antigen of interest, e.g., an antigen derived from a betacoronavirus structural protein, in particular, antigens derived from SARS-CoV-2 Spike protein.
  • the compositions of the invention e.g., vaccine compositions, do not comprise antigens per se, but rather comprise nucleic acids, in particular, mRNA(s) that encode antigens or antigenic sequences once delivered to a cell, tissue or subject.
  • nucleic acid molecules in particular mRNA(s) is achieved by formulating said nucleic acid molecules in appropriate carriers or delivery vehicles (e.g., lipid nanoparticles) such that upon administration to cells, tissues or subjects, nucleic acid is taken up by cells which, in turn, express protein(s) encoded by the nucleic acids, e.g., mRNAs.
  • mRNAs e.g., mRNAs.
  • antigen refers to a substance such as a protein (e.g., glycoprotein), polypeptide, peptide, or the like, which elicits an immune response, e.g., elicits an immune response when present in a subject (for example, when present in a human or mammalian subject).
  • the instant invention is based at least in part on the understanding that mRNA-encoded antigens, when expressed from mRNA administered to a cell or subject, can cause the immune system to produce an immune response to the expressed antigen, for example can trigger the production of antibodies against the expresses antigen, e.g., binding and/or neutralizing antibodies, can trigger B and or T cell responses specific to the expressed antigen, and ultimately can cause protective or prophylactic response against subsequent encounter with the antigen or with a pathogen with which the antigen is associated.
  • Preferred mRNA-encoded antigens are “viral antigens”.
  • the term “viral antigen” refers to an antigen derived from a virus, for example from a pathogenic virus.
  • antigen as used herein can refer to a full-length protein, for example, a full-length viral protein, or can refer to a fragment (e.g., a polypeptide or peptide fragment), subunit or domain of a protein, e.g., a viral protein subunit or domain.
  • a fragment e.g., a polypeptide or peptide fragment
  • subunit or domain of a protein e.g., a viral protein subunit or domain.
  • Many proteins have a quaternary or three-dimensional structure, which consists of more than one polypeptide or several polypeptide chains that associate into an oligomeric molecule.
  • subunit refers to a single protein molecule, for example, a polypeptide or polypeptide chain resulting from processing of a nascent protein molecule, which subunit assembles (or “coassembles”) with other protein molecules (e.g., subunits or chains) to form a protein complex.
  • Proteins can have a relatively small number of subunits and therefore be described as “oligomeric” or can consist of a large number of subunits and therefore be described as “multimeric”.
  • the subunits of an oligomeric or multimeric protein may be identical, homologous or totally dissimilar and dedicated to disparate tasks.
  • Proteins or protein subunits can further comprise domains.
  • domain refers to a distinct functional and/or structural unit within a protein. Typically, a “domain” is responsible for a particular function or interaction, contributing to the overall role of a protein. Domains can exist in a variety of biological contexts. Similar domains (i.e., domains sharing structural, functional and/or sequence homology) can exist within a single protein or can exist within distinct proteins having similar or different functions. A protein domain is often a conserved part of a given protein tertiary structure or sequence that can function and exist independently of the rest of the protein or subunit thereof.
  • antigen is distinct from the term “epitope” which is a substructure of an antigen, e.g., a polypeptide or carbohydrate structure, which may be recognized by an antigen binding site but is insufficient to induce an immune response.
  • the art describes protein antigens that are delivered to subjects or immune cells in isolated form, e.g., isolated protein, polypeptide or peptide antigens, however, the design, testing, validation, and production of protein antigens can be costly and time-consuming, especially when producing proteins at large scale.
  • mRNA technology is amenable to rapid design and testing of mRNA constructs encoding a variety of antigens.
  • antigens encoded by the mRNAs of the invention are expressed by the cells of the subject, e.g., are expressed by the human body, and thus the subject, e.g., the human body, serves as the “factory” to produce the antigens which, in turn, elicits the desired immune response.
  • antigens are proteins capable of inducing an immune response (e.g., causing an immune system to produce antibodies against the antigens).
  • antigen encompasses immunogenic proteins, as well as polypeptides or peptides derived from immunogenic proteins, for example immunogenic fragments (an immunogenic fragment that induces (or is capable of inducing) an immune response to an antigen, unless otherwise stated.
  • protein encompasses polypeptides and peptides and the term “antigen” encompasses antigenic fragments.
  • Other molecules may be antigenic such as bacterial polysaccharides or combinations of protein and polysaccharide structures, but for the viral vaccines included herein, viral proteins, fragments of viral proteins and designed and or mutated proteins derived from the betacoronavirus SARS-CoV-2 are the antigens featured herein.
  • nucleic acids particularly messenger RNA (mRNA) designed to encode an antigen of interest, e.g., a betacoronavirus spike protein antigen, subunit, domain or fragments (e.g., antigenic fragments) thereof.
  • mRNA messenger RNA
  • the nucleic acids, for example mRNAs, of the invention are preferably formulated in appropriate carriers or delivery vehicles (e.g., lipid nanoparticles), such that the nucleic acids, e.g., mRNAs are suitable for use in vivo.
  • nucleic acids e.g., mRNAs
  • mRNAs are capable of being delivered to cells and/or tissues within a subject, e.g., a human subject, to effectuate translation of protein encoded by these nucleic acids.
  • Nucleic acid molecules are macromolecules comprised of linked nucleotides that carry that carry genetic information and by directing the process of protein synthesis, direct most if not all cellular functions.
  • Nucleic acids comprise a polymer of nucleotides (nucleotide monomers). Thus, nucleic acids are also referred to as polynucleotides (also referred to as polynucleotide chains).
  • the two main classes of nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
  • DNA constitutes the genetic material in all free-living organisms and most viruses.
  • RNA is the genetic material of certain viruses, but it is also found in all living cells, where it plays an important role cellular processes, most notably the making of proteins.
  • Nucleosides are the structural subunit of nucleic acids such as DNA and RNA.
  • a nucleoside is composed of a nitrogenous base (a nucleobase), usually either a pyrimidine (cytosine, thymine or uracil) or a purine (adenine or guanine), covalently attached to a five- carbon carbohydrate ribose or “sugar” which is either ribose or deoxyribose.
  • Nucleotides consist of a nitrogenous base, a sugar (ribose or deoxyribose) and one to three phosphate groups. In essence, a nucleotide is simply a nucleoside with an additional phosphate group or groups.
  • the nucleic acid molecules are composed of nucleotides that are linked to one another in a chain by chemical bonds, called ester bonds, between the sugar base of one nucleotide and the phosphate group of the adjacent nucleotide.
  • the sugar is the 3' end, and the phosphate is the 5' end of each nucleotide.
  • the phosphate group attached to the 5' carbon of the sugar on one nucleotide forms an ester bond with the free hydroxyl on the 3' carbon of the next nucleotide.
  • bonds are called phosphodiester bonds, and the sugar-phosphate backbone is described as extending, or growing, in the 5' to 3' direction when the molecule is synthesized.
  • the nucleobase portion of nucleic acids features purine bases, adenine (A) and guanine (G), and pyrimidine bases, cytosine (C), thymine (T) in DNA, and uracil (U) in RNA.
  • the sugar portion of nucleic acids features deoxyribose in DNA, ribose in RNA.
  • the five nucleosides are commonly abbreviated to their one-letter codes A, G, C, T and U, respectively.
  • thymidine is more commonly written as “dT” (“d” represents “deoxy”) as it contains a 2'- deoxyribofuranose moiety rather than the ribofuranose ring found in uridine.
  • RNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • uridine is found in RNA and not DNA.
  • the remaining three nucleosides may be found in both RNA and DNA. In RNA, they would be represented as A, C and G whereas in DNA they would be represented as dA, dC and dG.
  • nucleic acid sequences set forth in the instant application may recite “T”s in a representative DNA sequence but where the sequence represents mRNA, the “T”s would be substituted for “IT’s.
  • any of the DNAs disclosed and identified by a particular sequence identification number herein also disclose the corresponding mRNA sequence complementary to the DNA, where each “T” of the DNA sequence is substituted with “U.”
  • Nucleic acids may be or may include, for example, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), e.g. mRNAs, threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a b- D-ribo configuration, a-LNA having an a-L-ribo configuration (a diastereomer of LNA), 2 amino-LNA having a 2'-amino functionalization, and 2'-amino- a-LNA having a 2'-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) and/or chimeras and/or combinations thereof.
  • DNAs deoxyribonucleic acids
  • RNAs ribonucleic acids
  • TAAs threose nucle
  • messenger RNAs particularly mRNAs designed to encode an antigen of interest, e.g., a betacoronavirus spike protein antigen, subunit, domain or fragments (e.g., antigenic fragments) thereof.
  • Messenger RNA a subtype of RNA, is a single-stranded molecule of RNA that corresponds to the genetic sequence of a gene. mRNA is created during the process of transcription wherein a single strand of DNA is decoded by RNA polymerase, and mRNA is synthesized, i.e., transcribed. mRNA is read by a ribosome in the process of synthesizing a protein, i.e., translation.
  • messenger RNA is an RNA that encodes a (at least one) protein (a naturally-occurring, non-naturally-occurring, or modified polymer of amino acids) and can be translated to produce the encoded protein in vitro, in vivo, in situ, or ex vivo.
  • compositions of the present disclosure comprise a (at least one) mRNA having an open reading frame (ORF) encoding a coronavirus antigen.
  • the mRNA further comprises a 5' UTR, 3' UTR, a poly(A) tail and/or a 5' cap or cap analog.
  • An open reading frame (ORF) is a continuous stretch of DNA or RNA beginning with a start codon (e.g., methionine (ATG or AUG)) and ending with a stop codon (e.g., TAA, TAG or TGA, or UAA, UAG or UGA).
  • An ORF typically encodes a protein.
  • sequences disclosed herein may further comprise additional elements, e.g., 5' and 3' UTRs, but that those elements, unlike the ORF, need not necessarily be present in an mRNA of the present disclosure.
  • the mRNAs if the invention, e.g., mRNAs featured in the betacoronavirus vaccines of the present disclosure may include any 5' untranslated region (UTR) and/or any 3' UTR.
  • UTR sequences are provided in the Sequence Listing (e.g., SEQ ID NOs: 2, 4, 131, and 132); however, other UTR sequences may be used or exchanged for any of the UTR sequences described herein.
  • UTRs may also be omitted from the mRNAs provided herein.
  • a composition comprises an mRNA that comprises a nucleotide sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleotide sequence of any one of SEQ ID NOs: 45, 75, or 90.
  • a composition comprises an mRNA that comprises a nucleotide sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleotide sequence of any one of the sequences in Tables 1- 15.
  • a composition comprises an mRNA that comprises an ORF having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleotide sequence of any one of SEQ ID NOs: 46, 76, or 91.
  • a composition comprises an mRNA that comprises an ORF having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the nucleotide sequence of any one of the sequences in Table 1-15.
  • any one of the antigens encoded by the mRNA described herein may or may not comprise a signal sequence.
  • coronavirus proteins determine the virus host tropism and entry into host cells.
  • Coronavirus spike (S) protein is a choice antigen for the vaccine design as it can induce neutralizing antibodies and protective immunity.
  • S protein is critical for SARS-CoV-2 infection.
  • the organization of the S protein is similar among betacoronaviruses, such as SARS-CoV-2, SARS-CoV, MERS-CoV, HKUl-CoV, MHV-CoV and NL63-CoV.
  • the term “Spike protein” refers to a glycoprotein that that forms homotrimers protruding from the envelope (viral surface) of vimses including betacoronaviruses. Trimerized Spike protein facilitates entry of the virion into a host cell by binding to a receptor on the surface of a host cell followed by fusion of the viral and host cell membranes.
  • the S protein is a highly glycosylated and large type I transmembrane fusion protein that is made up of 1,160 to 1,400 amino acids, depending upon the type of virus.
  • Betacoronavirus Spike proteins comprise between about 1100 to 1500 amino acids and comprise the structure (i.e., the domain composition and organization) as set forth in FIG. 1.
  • SARS-CoV-2 spike (S) protein is a choice antigen for the vaccine design as it can induce neutralizing antibodies and protective immunity.
  • mRNAs of the invention are designed to produce SARS-CoV-2 Spike proteins (i.e., encode Spike proteins such that Spike protein is expressed when the mRNA is delivered to a cell or tissue, for example a cell or tissue in a subject), as well as antigenic variants thereof.
  • Spike protein may be necessary for a vims, e.g., a betacoronavirus, to perform its intended function of facilitating virus entry into a host cell
  • a certain amount of variation in Spike protein structure and/or sequence is tolerated when seeking primarily to elicit an immune response against Spike protein.
  • minor truncation e.g., of one to a few, possibly up to 5 or up to 10 amino acids from the N- or C-terminus of the encoded Spike protein, e.g., encoded Spike protein antigen, may be tolerated without changing the antigenic properties of the protein.
  • a Spike protein e.g., an encoded Spike protein antigen
  • a Spike protein e.g., an encoded Spike protein antigen
  • the variant preferably has the same activity as the reference Spike protein sequence and/or has the same immune specificity as the reference Spike protein, as determined for example, in immunoassays (e.g., enzyme-linked immunosorbent assays (ELISA assays).
  • immunoassays e.g., enzyme-linked immunosorbent assays (ELISA assays).
  • S proteins of coronaviruses can be divided into two important functional subunits, of which include the N-terminal SI subunit, which forms of the globular head of the S protein, and the C-terminal S2 region that forms the stalk of the protein and is directly embedded into the viral envelope.
  • the S 1 subunit Upon interaction with a potential host cell, the S 1 subunit will recognize and bind to receptors on the host cell, specifically angiotensin-converting enzyme 2 (ACE2) receptors, whereas the S2 subunit, which is the most conserved component of the S protein, will be responsible for fusing the envelope of the virus with the host cell membrane.
  • ACE2 angiotensin-converting enzyme 2
  • Each monomer of trimeric S protein trimer contains the two subunits, SI and S2, mediating attachment and membrane fusion, respectively. See, e.g., FIG. 1.
  • the two subunits are separated from each other by an enzymatic cleavage process.
  • S protein is first cleaved by furin-mediated cleavage at the S1/S2 site in infected cells, In vivo, a subsequent serine protease-mediated cleavage event occurs at the S2' site within SI.
  • the S1/S2 cleavage site is at amino acids 676 - TOTNSPRRAR/SVA - 688 (referencing SEQ ID NO: 127).
  • the S2’ cleavage site is at amino acids 811 - KPSKR/SFI - 818 (referencing SEQ ID NO: 126).
  • SI subunit e.g., SI subunit antigen
  • S2 subunit e.g., S2 subunit antigen
  • Spike protein S 1 or S2 subunit may be necessary for receptor binding or membrane fusion, respectively, a certain amount of variation in S 1 or S2 structure and/or sequence is tolerated when seeking primarily to elicit an immune response against Spike protein subunits.
  • minor tmncation e.g., of one to a few, possibly up to 4, 5, 6, 7, 8, 9 or 10 amino acids from the N- or C-terminus of the encoded subunit, e.g., encoded SI or S2 protein antigens, may be tolerated without changing the antigenic properties of the protein.
  • a Spike protein e.g., an encoded Spike protein antigen
  • a Spike protein subunit e.g., an encoded SI or S2 protein antigen
  • the variant preferably has the same activity as the reference Spike protein subunit sequence and/or has the same immune specificity as the reference Spike protein subunit, as determined for example, in immunoassays (e.g., enzyme-linked immunosorbent assays (ELISA assays).
  • immunoassays e.g., enzyme-linked immunosorbent assays (ELISA assays).
  • the SI and S2 subunits of the SARS-CoV-2 Spike protein further include domains readily discemable by structure and function, which in turn can be featured in designing antigens to be encoded by the nucleic acid vaccines, in particular, mRNA vaccines of the invention.
  • domains include the N-terminal domain (NTD) and the receptor-binding domain (RBD), said RBD domain further including a receptor-binding motif (RBM).
  • the wild type SI subunit also includes a signal peptide (SD), N-terminal to the NTD domain and a first subdomain (SD1) and second subdomain (SD2).
  • domains include fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), transmembrane domain (TM), and cytoplasm domain, also known as cytoplasmic tail (CT) (Lu R. et ah, supra; Wan et al., J. Virol. Mar 2020, 94 (7) e00127-20).
  • the HR1 and HR2 domains can be referred to as the “fusion core region” of SARS-CoV-2 (Xia et al., 2020 Cell Mol Immunol. Jan; 17(1): 1-12.).
  • FIG. 1 depicts the domain architecture in the SARS-CoV-2 Spike protein.
  • the SI subunit includes an N terminal domain (NTD), a linker region, a receptor binding domain (RBD), a first subdomain (SD1), and a second subdomain (SD2).
  • An SI subunit may be modified to add a C-terminal transmembrane domain (TM) or it may be soluble.
  • the S2 subunit includes, inter alia, a first heptad repeat (HR1), a second heptad repeat (HR2), a transmembrane domain (TM), and a cytoplasmic tail.
  • a soluble S2 subunit may be generated without a TM domain.
  • NTD and RBD of S 1 are good antigens for the vaccine design approach of the invention as these domains have been shown to be the targets of neutralizing antibodies in betacoronavirus-infected individuals.
  • N-terminal domain refers to a domain within the SARS-CoV-2 SI subunit comprising approximately 290 amino acids in length, having identity to amino acids 1-290 of the SI subunit of the Spike protein having the amino acid sequence set forth as SEQ ID NO: 125.
  • the term “receptor binding domain” or “RBD” refers to a domain within the SI subunit of SARS-CoV-2 comprising approximately 175- 225 amino acids in length, having identity to amino acids 316-517 of the SI subunit of the Spike protein having the amino acid sequence set forth as SEQ ID NO: 125.
  • the term “receptor binding motif’ refers to the portion of the RBD that directly contacts the ACE2 receptor. Expressed RBDs are predicted to specifically bind to angiotensin-converting enzyme 2 (ACE2) as its receptor and/or specifically react with RBD-binding and/or neutralizing antibodies, e.g., CR3022.
  • compositions provided herein include mRNA that may encode any one or more full- length or partial (truncated or other deletion of sequence) S protein subunit (e.g., S 1 or S2 subunit), one or more domain or combination of domains of an S protein subunit (e.g., NTD, RBD, or NTD-RBD fusions, with or without an SD1 and/or SD2), or chimeras of full-length or partial and S2 protein subunits.
  • S protein subunit and/or domain configurations are contemplated herein.
  • FIG. 2 and FIG. 6 depict exemplary domain and subunit antigens derived from the SARS-CoV-2 Spike protein.
  • FIG. 2 A and 2B depict soluble and transmembrane RBD antigens respectively.
  • a transmembrane NTD antigen is shown in FIG. 2C.
  • the domain antigens shown in FIGs. 2D-2F and 21 represent exemplary fusion proteins of NTD and RBD, each with a SP and TM domain.
  • Two of the constructs also have a terminal trafficking domain (CD86 and/or CD1 lb).
  • the domains are linked through linkers, in particular GS linkers or a PADRE linker (FIG. 21).
  • Domain constructs having an RBD domain N-terminal to an NTD domain are depicted in FIGs. 2G and 2H. Each construct may also include a SP and/or TM domain.
  • compositions comprising an mRNA that encodes a (at least one) subunit of a SARS-CoV-2 S protein.
  • the mRNA encodes an SI subunit (e.g., full length or partial).
  • the mRNA encodes an S2 subunit (e.g., full length or partial).
  • the mRNA encodes a chimeric S1-S2 protein, wherein one of the subunits is from a SARS-CoV-2 S protein, and the other subunit is from another organism, e.g., a virus, such influenza virus.
  • the SARS-CoV-2 subunits (SI and/or S2) encoded by the mRNA of the present disclosure may be soluble or membrane bound (e.g., linked to a transmembrane domain).
  • Exemplary antigen designs based on S2 are shown in FIG. 6.
  • FIG. 6A depicts a full length S2, including the FP, HR1, HR2, TM and CT domains.
  • a version of S2 comprised of linkers between subunits is shown in FIG. 6B.
  • Domain antigens without the CT domain are shown in FIG. 6C and 6D.
  • a soluble protein is present in the cytoplasm of a cell or is secreted from a cell (e.g., not membrane bound).
  • Soluble antigens secreted by cells may be opsonized by complement and captured by follicular dendritic cells in lymph nodes, where they may be recognized by B cells specific to epitopes present on the expressed protein.
  • the expression of subunit antigens further allows focusing of the immune response to specific subunits and with minimal stimulation of memory B and T cells specific to other domains of the antigen that are shared with other related viruses.
  • an mRNA provided herein encodes a soluble SARS-CoV-2 SI subunit antigen and/or a soluble SARS-CoV-2 S2 subunit antigen.
  • a soluble SARS-CoV-2 SI subunit antigen and the mRNA encoding it is provided in Tables 1A and IB below.
  • Other examples of soluble SARS-CoV-2 subunit antigens are provided herein. Table 1A. Soluble Subunit Antigen
  • a membrane bound protein is anchored in a cell membrane (not soluble). Without being bound by theory, it is thought that antigen presenting cells will carry the embedded antigen to the draining lymph nodes to generate a strong immune response.
  • the germinal center reaction that occurs in the draining lymph node involves prolonged contact between CD4 + TFH cells and B cells, allowing co-stimulation and local cytokine signals such as IL-4 and IL-21 that favor replication of B cells specific to the presented antigen and class switching to the production of IgGl, each of which may promote the generation of long-lived plasma cells and memory B cells.
  • an mRNA encodes a membrane bound SARS-CoV-2 S 1 subunit antigen and/or a membrane bound SARS-CoV-2 S2 subunit antigen.
  • a membrane bound antigen e.g., SI subunit, S2 subunit, NTD, RBD, or any combination thereof
  • a transmembrane domain e.g., a naturally occurring transmembrane domain or a heterologous transmembrane domain (derived from a heterologous protein), which is responsible for anchoring the protein in the cell membrane.
  • a non-limiting example of a membrane bound SARS-CoV-2 SI subunit antigen and a SARS-CoV-2 S2 subunit antigen and the mRNA encoding them are provided in Tables 2A and 2B below.
  • Other membrane bound SARS-CoV-2 S 1 subunit antigens are contemplated herein.
  • a composition comprises an mRNA that encodes an S 1 subunit that has been modified to remove the RBD or a portion of the RBD. Truncation of the S 1 subunit provides fewer epitopes for the immune system to recognize, thereby biasing the immune response to the remaining epitopes, which may select for antibodies to specific epitopes that are important for virus neutralization. Truncation or partial deletion of the RBD may prevent the expressed protein or cells carrying it from interacting with receptor ACE2, making it more likely to reach the lymph node and stimulate a desired immune response. Furthermore, removing the RBD may prevent epitope masking by cross-reactive antibodies previously raised against related viruses, and thus focus the elicited immune response toward the desired antigen specifically.
  • removal of the RBD may alter the conformation of the expressed subunit, allowing B cells specific to these alternative conformational epitopes to uptake and present linear peptides to T cells, thereby indirectly enhancing the CD4 + T cell response to those epitopes, which are still present in the native conformation.
  • a composition comprises an mRNA that encodes an S 1 subunit that has been modified to remove the RBD or a portion of the RBD, wherein the S2 subunit contains a glycan.
  • Glycans are attached to proteins by N-linked glycosylation via asparagine residues or O-linked glycosylation on serine or threonine residues. The presence of a glycan shield on some components of a protein may mask peptide epitopes, thereby focusing the antibody response towards other exposed peptide epitopes. Furthermore, glycosylated proteins also elicit antibodies that recognize the coating glycans. B cells that recognize the glycan epitope will intake and present linear peptide epitopes to CD4 + T cells, thereby boosting the CD4 + T cell response to linear epitopes found throughout the protein.
  • Non-limiting examples of truncated SARS-CoV-2 SI subunit antigens and the mRNA encoding them are provided in Tables 3 A and 3B below.
  • Non-limiting examples of SARS-CoV-2 SI subunits having an RBD deletion and the mRNA encoding them are provided in Tables 4A and 4B below.
  • a composition comprises an mRNA that encodes a chimeric protein, for example a chimeric S1-S2 protein with an SI subunit from an S protein of one virus and an S2 subunit from an S protein of another, different virus.
  • a chimeric protein for example a chimeric S1-S2 protein with an SI subunit from an S protein of one virus and an S2 subunit from an S protein of another, different virus.
  • an S2 subunit may be from SARS-CoV-2, while the SI subunit may be from HKU1.
  • an S2 subunit may be from SARS-CoV-2, while the S 1 subunit may be from OC43.
  • chimeric proteins are likely to be opsonized by circulating antibodies specific to the SI subunit of HKU1 or OC43 generated by previous exposures, promoting efficient uptake and cross-presentation of SARS-CoV-2 S2 subunit peptides to CD4 + T cells by macrophages and dendritic cells.
  • Opsonization by circulating antibodies also promotes capture by follicular dendritic cells for presentation to B cells with receptors specific to SARS-CoV-2 S2 subunit epitopes.
  • Non-limiting examples of chimeric S 1/S2 subunit constructs and the mRNA encoding them are provided in Tables 5 A and 5B below.
  • compositions comprising an mRNA that encodes a (at least one) subdomain of the SARS-CoV-2 SI subunit of the S protein.
  • the subdomain may be an N-terminal domain (NTD) or a receptor binding domain (RBD) (with or without the SD1 and/or SD2).
  • NTD N-terminal domain
  • RBD receptor binding domain
  • an mRNA encodes a combination (e.g., a non-natural combination) of an NTD and an RBD (with or without the SD1 and/or SD2).
  • the NTD and/or RBD is linked to a transmembrane domain (with or without the SD1 and/or SD2).
  • the mRNA encodes two subdomains of the SARS- CoV-2 S 1 subunit of the S protein (NTD and RBD) that have been mutated to comprise cysteine residues. Such mutations, in some embodiments, result in the formation of a disulfide bond.
  • an mRNA may encode an NTD comprising an F43C mutation and an RBD comprising a Q563C mutation, ultimately resulting in a an NTD linked to an RBD via disulfide bond.
  • N Terminal Domain (NTD) Constructs
  • an mRNA provided herein encodes an NTD of an SI subunit of a SARS-CoV-2 S protein.
  • the NTD of certain betacoronaviruses elicits protective levels of antibodies.
  • Antibodies specific to the NTD of other betacoronaviruses such as MERS act by preventing membrane fusion and viral entry (Zhou H et al. Nat Commun. 2019; 3068), providing a second mechanism of neutralization that is distinct from preventing viral attachment to ACE2.
  • the SARS-CoV-2 NTDs encoded by an mRNA of the present disclosure may be soluble or membrane bound.
  • a non-limiting example of a membrane bound SARS-CoV-2 NTD antigen and the mRNA encoding it is provided in Tables 6A and 6B below. Table 6A.
  • an mRNA provided herein encodes an RBD of an SI subunit of a SARS-CoV-2 S protein.
  • the RBD binds ACE2 receptors on host cells, which mediate virus attachment to cells. Attachment is necessary for the virus to enter cells and replicate.
  • RBD targeted antibody responses, which block virus attachment into the cell, effectively neutralize extracellular virus particles, preventing proliferation and promoting further immune responses to other components of the neutralized virus particles.
  • the SARS-CoV-2 RBDs encoded by an mRNA of the present disclosure may be soluble or membrane bound (e.g., linked to a transmembrane domain).
  • an mRNA encodes a soluble SARS-CoV-2 RBD.
  • Dendritic cells sample soluble proteins by pinocytosis and, upon migrating to the draining lymph node, present linear peptides that comprise the sampled protein to CD4 + T cells. These CD4 + T cells provide proliferation signals to B cells that have recognized, taken up, and presented an epitope from the RBD, so administration of specifically RBD without other components of the SARS-CoV-2 spike protein expected to focus the immune response towards the epitopes present in the RBD.
  • Non- limiting examples of soluble SARS-CoV-2 RBDs and the mRNA encoding them are provided in the Tables 7 A and 7B below.
  • an mRNA encodes a membrane bound SARS-CoV-2 RBD.
  • Cells expressing membrane bound RBD are expected to carry these membrane-bound antigens to the draining lymph node and promote efficient recognition of epitopes by RBD-specific B cells. Because the B cell surface contains many surface bound antibodies and the expressing cell contains many copies of the membrane bound RBD, it is expected that initial recognition of antigen by a B cell will be followed by cross-linking of B cell receptors, stimulating a strong response through an avidity effect.
  • Non-limiting examples of membrane bound SARS-CoV-2 RBDs and the mRNA encoding them are provided in Tables 8A and 8B below.
  • an mRNA provided herein encodes a SARS-CoV-2 NTD-RBD fusion protein.
  • the NTD and the RBD of a SARS-CoV-2 SI subunit of an S protein may be linked to each other through a linker, such as a short amino acid (e.g., glycine-serine) linker to allow flexibility/hinging and space between the domains.
  • a linker comprising an antigenic epitope, e.g., a Class II universal T cell epitope such as PADRE, can be used.
  • a transmembrane region is linked to the NTD-RBD fusion, for example, through another short amino acid (e.g., glycine-serine or PADRE) linker for flexibility and to permit a reasonable distance between the membrane and the antigen.
  • another short amino acid e.g., glycine-serine or PADRE
  • this membrane bound, tandem configuration presents most, if not all, known neutralizing and protective epitopes in one open reading frame.
  • Administration of this fusion protein should then focus the immune response towards known protective epitopes and reduce the unnecessary generation of antibodies and T cells specific to non-protective epitopes.
  • antibodies to different domains may neutralize virus particles through different mechanisms, such as by blocking attachment to host cells or preventing bound virus from undergoing membrane fusion and entering host cells.
  • Linkers are simply amino acid sequences that artificially link together two other amino acid sequences.
  • Linkers used herein may be cleavable or non-cleavable.
  • Cleavable linkers allow an mRNA to be translated into a polypeptide, after which cleavage of the linker allows each individual component to be released independently.
  • Non-cleavable linkers keep one or more protein subunits connected, allowing the whole protein to perform a function that requires close proximity of the component subunits.
  • Non-limiting examples of such linkers include glycine- serine (GS) linkers (non-cleavable); and F2A linker, P2A linker, T2A linker, and E2Alinker (cleavable). Other links may be used herein.
  • GS glycine- serine
  • F2A linker P2A linker
  • T2A linker T2A linker
  • E2Alinker cleavable
  • the linker is a GS linker.
  • GS linkers are polypeptide linkers that include glycine and serine amino acids repeats. They comprise flexible and hydrophilic residues and can be used to perform fusion of protein subunits without interfering in the folding and function of the protein domains, and without formation of secondary structures.
  • an mRNA encodes a fusion protein that comprises a GS linker that is 3 to 20 amino acids long.
  • the GS linker may have a length of (or have a length of at least)
  • a GS linker is (or is at least) 15 amino acids long (e.g., GGSGGSGGSGGSGGG (SEQ ID NO: 133)). In some embodiments, a GS linker is (or is at least) 8 amino acids long (e.g., GGGSGGGS (SEQ ID NO: 134)). In some embodiments, a GS linker is (or is at least) 7 amino acids long (e.g., GGGSGGG (SEQ ID NO: 135)). In some embodiments, a GS linker is (or is at least) 4 amino acid long (e.g., GGGS (SEQ ID NO: 136)).
  • the GS linker comprises (GGGS)n (SEQ ID NO: 136), where n is any integer from 1-5.
  • a GS linker is (or is at least) 4 amino acid long (e.g., GSGG (SEQ ID NO: 152)).
  • the GS linker comprises (GSGG)n (SEQ ID NO: 152), where n is any integer from 1-5.
  • a linker is a glycine linker, for example having a length of (or a length of at least) 3 amino acids (e.g., GGG).
  • a protein encoded by an mRNA vaccine includes more than one linker, which may be the same or different from each other (e.g., GGGSGGG (SEQ ID NO: 135) and GGGS (SEQ ID NO: 136) in the same S protein construct).
  • a linker comprises mRNA encoding a pan HLA DR-binding epitope (PADRE) (e.g., AKFV A AWTLKA A A (SEQ ID NO: 148)).
  • PADRE pan HLA DR-binding epitope
  • PADRE is an immunodominant helper CD4 T cell epitope and a potent immunogen (See, e.g., Alexander J. et al. J of Immuno. 164(3): 1625-33, incorporated herein by reference).
  • an mRNA encodes a SARS-CoV-2 S protein domain (e.g., NTD, RBD, or NTD-RBD fusion) linked to a Golgi trafficking signal.
  • SARS-CoV-2 S protein domain e.g., NTD, RBD, or NTD-RBD fusion
  • Non-limiting examples of such signals include macrophage markers, such as CD86 and/or CD1 lb, which are highly expressed and the intracellular region may control efficient export from the Golgi apparatus to the cell surface.
  • Other cell trafficking signals may be used herein, for example, the VSV-G cytosolic tail (VSVGct). More efficient trafficking of encoded proteins to the cell surface is expected to increase antigen availability for B cell recognition and therefore promote the generation of antibodies to the encoded SARS-CoV-2 S protein domains.
  • SARS-CoV-2 antigens linked to a trafficking signal and the mRNA encoding them are provided in Tables 10A and 10B below.
  • an mRNA provided herein encodes a SARS-CoV-2 NTD-RBD fusion protein in which some portion of the C-terminal domain has been truncated/deleted.
  • 13 (or at least 13) amino acids have been deleted from the C-terminal domain of the NTD-RBD fusion protein. Deletion of these amino acids is expected to increase exposure of epitopes to antibodies, thereby stimulating a more robust immune response to protective epitopes present on the NTD and RBD domains.
  • SARS-CoV-2 domain fusion antigen having a C-terminal truncation and the mRNA encoding it is provided in Tables 11A and 11B below.
  • SARS-CoV-2 S protein domain antigens include “extended” regions that include sequences adjacent to and/or flanking what is understood in the art to be the NTD domain or the RBD domain.
  • the RBD_EXT series encompasses the SD1 (subdomain 1).
  • the NTD_EXT series encompasses a C-terminal helix in the NTD.
  • NTD and RBD domains not only can provide additional B-cell epitopes to the antigen, but may potentially result in more optimal folding of those domains and stimulate B cells with antibodies specific to epitopes that may be found on the edge of either domain. Furthermore, the inclusion of these extension sequences may thus increase the distance between the NTD or RBD and the expressing cell membrane, increasing exposure of both domains to antibodies that may bind less efficiently if the expressed protein was too close to the cell surface.
  • extension sequences increases the pool of peptides that could potentially be presented to CD4 + T cells by B cells that have recognized an NTD or RBD epitope, then processed the entire protein for antigen presentation, thereby increasing the chance that an NTD or RBD-specific B cell receives sufficient T cell help.
  • SARS-CoV-2 domain extensions and the mRNA encoding them are provided in Tables 12A and 12B below. Table 12. Domain Extensions
  • compositions that comprise a mixture of mRNAs encoding SARS-CoV-2 S protein subdomains.
  • a composition comprises a mixture of an mRNA encoding an NTD (with or without SD1, SD2, and/or a transmembrane domain) and an mRNA encoding an RBD (with or without SD1, SD2, and/or a transmembrane domain).
  • a composition comprises an mRNA (e.g., SEQ ID NO: 45 or 46) encoding an NTD linked to a transmembrane domain (e.g., SEQ ID NO: 47) and an mRNA (e.g., SEQ ID NO: 75 or 76 encoding an RBD linked to a transmembrane domain (e.g., SEQ ID NO: 77).
  • an mRNA e.g., SEQ ID NO: 45 or 46
  • an mRNA e.g., SEQ ID NO: 75 or 76 encoding an RBD linked to a transmembrane domain (e.g., SEQ ID NO: 77).
  • the ratio of the concentration of one mRNA to another in a composition may be 1:1 (50:50), 1:2, 1:3, 1:4, or 1:5. In some embodiments, the ratio is 1:1.
  • a composition may comprise a 1:1 ratio of an mRNA (e.g., SEQ ID NO: 45 or 46) encoding an NTD linked to a transmembrane domain (e.g., SEQ ID NO: 47) to an mRNA (e.g., SEQ ID NO: 75 or 76 encoding an RBD linked to a transmembrane domain (e.g., SEQ ID NO: 77). In some embodiments, the ratio is 1:2.
  • a composition may comprise a 1:2 ratio of an mRNA (e.g., SEQ ID NO: 45 or 46) encoding an NTD linked to a transmembrane domain (e.g., SEQ ID NO: 47) to an mRNA (e.g., SEQ ID NO: 75 or 76) encoding an RBD linked to a transmembrane domain (e.g., SEQ ID NO: 77).
  • an mRNA e.g., SEQ ID NO: 45 or 46
  • an NTD linked to a transmembrane domain e.g., SEQ ID NO: 47
  • an mRNA e.g., SEQ ID NO: 75 or 76
  • RBD linked to a transmembrane domain
  • a composition may comprise a 1:2 ratio of an mRNA (e.g., SEQ ID NO: 75 or 76) encoding an RBD linked to a transmembrane domain (e.g., SEQ ID NO: 77) to an mRNA (e.g., SEQ ID NO: 45 or 46) encoding an NTD linked to a transmembrane domain (e.g., SEQ ID NO: 47).
  • an mRNA e.g., SEQ ID NO: 75 or 76
  • an mRNA e.g., SEQ ID NO: 45 or 46
  • NTD linked to a transmembrane domain
  • mRNA vaccines provided herein encode fusion proteins that comprise coronavirus antigens linked to a scaffold domain.
  • a scaffold domain imparts desired properties to an antigen encoded by an mRNA of the disclosure.
  • scaffold domain may improve the immunogenicity of an antigen, e.g., by altering the structure of the antigen, altering the uptake and processing of the antigen, and/or causing the antigen to bind to another molecule.
  • a scaffold domain linked to antigen facilitates self-assembly of the antigen into a viral nanoparticle or a larger protein-folded immunogen.
  • Non-limiting examples of scaffold domains that may be used as provide herein include, ferritin domains, lumazine synthetase domains, foldon domains, and encapsulin domains. Other scaffold domains may be used.
  • a ferritin domain is used as a scaffold domain.
  • Ferritin is a protein, the main function of which is intracellular iron storage.
  • Ferritin is comprised of twenty-four (24) subunits, each composed of a four- alpha-helix bundle that self-assemble into a quaternary structure with octahedral symmetry (Cho K. J. et al. J Mol Biol. 2009; 390: 83-98; (Granier T. et al. J Biol Inorg Chem. 2003; 8: 105-111; and Lawson D.M. et al. Nature. 1991; 349: 541-544). Ferritin self-assembles into nanoparticles with robust thermal and chemical stability.
  • ferritin nanoparticles Enclosing antigens within ferritin nanoparticles in this manner is expected to both delay degradation of the antigen and aggregate individual antigens, with each nanoparticle containing twenty-four (24) antigen subunits. Aggregation of multiple copies of the same antigen enhances both antigen uptake and migration by dendritic cells, as well as more robust CD4 + and CD8 + T cell responses (Kastenmiiller K et al. J Clin Invest. 2011; 121(5): 1782-96). Thus, the ferritin nanoparticle is a well-suited platform for antigen presentation and vaccine development.
  • An mRNA provided herein encodes an RBD linked to a ferritin domain, for example, through a glycine (e.g., GGG) linker domain.
  • GGG glycine linker domain
  • an mRNA provided herein encodes an S 1 domain of an S protein linked to a ferritin domain, for example, through a glycine (e.g., GGG) linker. As indicated elsewhere herein, other linkers may be used.
  • GGG glycine
  • Non-limiting examples of SARS-CoV-2 antigens linked to a ferritin domain and the mRNA encoding them are provided in Tables 13A and 13B below.
  • a lumazine synthetase domain is used as a scaffold domain.
  • Lumazine synthetase is an enzyme responsible for the penultimate catalytic step in the biosynthesis of riboflavin in a variety of organisms, including archaea, bacteria, fungi, plants, and eubacteria.
  • Lumazine synthetase is composed of homooligomers, which vary in size and subunit number, including pentamers, decamers, and icosahedral sixty-mers, depending on its species of origin.
  • the lumazine synthetase monomer is 150 amino acids long and includes beta- sheets with flanking, tandem alpha-helices.
  • lumazine synthetase Different quaternary structures have been reported for lumazine synthetase, illustrating its morphological versatility: from homopentamers up to symmetrical assemblies of twelve (12) pentamers forming capsids of 150 A diameter. Presentation of antigens on the surface of lumazine synthetase results in a high local concentration of antigens displayed in an ordered array. Such repetitive structures enable the cross-linking of B-cell receptors and result in strong immune responses through an avidity effect.
  • An mRNA provided herein encodes an RBD linked to a lumazine synthetase domain, for example, through a glycine- serine (e.g., GGS). Other linkers may be used.
  • an mRNA provided herein encodes an S 1 domain of an S protein linked to a lumazine synthetase domain, for example, through a glycine-serine (e.g., GGS) linker. As indicated elsewhere herein, other linkers may be used.
  • a glycine-serine e.g., GGS
  • other linkers may be used.
  • SARS-CoV-2 antigens linked to a foldon domain and the mRNA encoding them are provided in Tables 14A and 14B below.
  • a foldon domain is used as a scaffold domain.
  • the C-terminal domain of T4 fibritin (foldon) is obligatory for the formation of the fibritin trimer structure and can be used as an artificial trimerization domain (see, e.g., Meier S. et al. Journal of Molecular Biology 2004 Dec 3; 344(4): 1051-1069; Tao Y et al. Structure 1997 Jun 15; 5(6):789-98).
  • a foldon domain promotes correct trimerization of the S protein, thus avoiding misfolding of the protein.
  • Such a process resulting in production of the prefusion conformation of the S protein results in increased expression, conformational homogeneity, and elicitation of potent neutralizing antibody responses.
  • an encapsulin domain is used as a scaffold domain.
  • Encapsulin is a protein cage nanoparticle isolated from the thermophile Thermotoga maritima.
  • An mRNA provided herein encodes an S protein domain (e.g.,
  • SI, S2, RBD, and/or NTD linked to an encapsulin domain.
  • a composition of the present disclosure includes an mRNA encoding an antigenic fusion protein.
  • the encoded antigen or antigens may include two or more proteins (e.g., protein and/or protein fragment) joined together.
  • the protein to which a protein antigen is fused does not promote a strong immune response to itself, but rather to the coronavirus antigen.
  • Antigenic fusion proteins retain the functional property from each original protein.
  • a fusion protein comprises a receptor binding domain from a SARS-CoV-2 Spike protein.
  • a fusion protein comprises an N-terminal domain from a SARS- CoV-2 Spike protein
  • a fusion protein comprises a transmembrane domain.
  • the transmembrane domain may, in some embodiments, be from a virus that is not SARS-CoV-2.
  • the transmembrane domain may be from an influenza hemagglutinin transmembrane domain, which has been demonstrated to effectively anchor proteins at the cell surface.
  • compositions of the present disclosure include RNA that encodes a coronavirus antigen variant.
  • Antigen variants or other polypeptide variants refers to molecules that differ in their amino acid sequence from a wild-type, native, or reference sequence.
  • the antigen/polypeptide variants may possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence, as compared to a native or reference sequence.
  • variants possess at least 50% identity to a wild-type, native or reference sequence.
  • variants share at least 80%, or at least 90% identity with a wild-type, native, or reference sequence.
  • Variant antigens/polypeptides encoded by nucleic acids of the disclosure may contain amino acid changes that confer any of a number of desirable properties, e.g., that enhance their immunogenicity, enhance their expression, and/or improve their stability or PK/PD properties in a subject.
  • Variant antigens/polypeptides can be made using routine mutagenesis techniques and assayed as appropriate to determine whether they possess the desired property. Assays to determine expression levels and immunogenicity are well known in the art and exemplary such assays are set forth in the Examples section.
  • PK/PD properties of a protein variant can be measured using art recognized techniques, e.g., by determining expression of antigens in a vaccinated subject over time and/or by looking at the durability of the induced immune response.
  • the stability of protein(s) encoded by a variant nucleic acid may be measured by assaying thermal stability or stability upon urea denaturation or may be measured using in silico prediction. Methods for such experiments and in silico determinations are known in the art.
  • a composition comprises an mRNA or an mRNA ORF that comprises a nucleotide sequence of any one of the sequences provided herein (see, e.g.,
  • Sequence Listing or comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a nucleotide sequence of any one of the sequences provided herein.
  • identity refers to a relationship between the sequences of two or more polypeptides (e.g. antigens) or polynucleotides (nucleic acids), as determined by comparing the sequences. Identity also refers to the degree of sequence relatedness between or among sequences as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., “algorithms”). Identity of related antigens or nucleic acids can be readily calculated by known methods.
  • Percent (%) identity as it applies to polypeptide or polynucleotide sequences is defined as the percentage of residues (amino acid residues or nucleic acid residues) in the candidate amino acid or nucleic acid sequence that are identical with the residues in the amino acid sequence or nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art. It is understood that identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation.
  • variants of a particular polynucleotide or polypeptide have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art.
  • tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res.
  • sequence tags or amino acids such as one or more lysines
  • Sequence tags can be used for peptide detection, purification or localization.
  • Lysines can be used to increase peptide solubility or to allow for biotinylation.
  • amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences.
  • Certain amino acids e.g., C-terminal or N-terminal residues
  • sequences for (or encoding) signal sequences, termination sequences, transmembrane domains, linkers, multimerization domains (such as, e.g., foldon regions) and the like may be substituted with alternative sequences that achieve the same or a similar function.
  • cavities in the core of proteins can be filled to improve stability, e.g., by introducing larger amino acids.
  • buried hydrogen bond networks may be replaced with hydrophobic resides to improve stability.
  • glycosylation sites may be removed and replaced with appropriate residues.
  • sequences are readily identifiable to one of skill in the art. It should also be understood that some of the sequences provided herein contain sequence tags or terminal peptide sequences (e.g., at the N-terminal or C-terminal ends) that may be deleted, for example, prior to use in the preparation of an mRNA vaccine.
  • protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of coronavirus antigens of interest.
  • any protein fragment meaning a polypeptide sequence at least one amino acid residue shorter than a reference antigen sequence but otherwise identical
  • an antigen includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations, as shown in any of the sequences provided or referenced herein.
  • Antigens/antigenic polypeptides can range in length from about 4, 6, or 8 amino acids to full length proteins.
  • Naturally-occurring eukaryotic mRNA molecules can contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5 '-end (5' UTR) and/or at their 3 '-end (3' UTR), in addition to other structural features, such as a 5 ’-cap structure or a 3'-poly(A) tail.
  • UTR untranslated regions
  • Both the 5' UTR and the 3' UTR are typically transcribed from the genomic DNA and are elements of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5 '-cap and the 3'-poly(A) tail are usually added to the transcribed (premature) mRNA during mRNA processing.
  • a composition includes an mRNA having an open reading frame encoding at least one antigenic polypeptide having at least one modification, at least one 5' terminal cap, and is formulated within a lipid nanoparticle.
  • 5 '-capping of polynucleotides may be completed concomitantly during the in vitro-transcription reaction using the following chemical RNA cap analogs to generate the 5'-guanosine cap structure according to manufacturer protocols: 3'-0-Me-m7G(5')ppp(5') G [the ARCA cap];G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA).
  • 5'-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the “Cap 0” structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA).
  • Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2'-0 methyl-transferase to generate: m7G(5')ppp(5')G-2'-0-methyl.
  • Cap 2 structure may be generated from the Cap 1 stmcture followed by the 2'-0-methylation of the 5 '-antepenultimate nucleotide using a 2'-0 methyl- transferase.
  • Cap 3 structure may be generated from the Cap 2 structure followed by the 2'-0- methylation of the 5'-preantepenultimate nucleotide using a 2'-0 methyl-transferase.
  • Enzymes may be derived from a recombinant source.
  • the 3'-poly(A) tail is typically a stretch of adenine nucleotides added to the 3 '-end of the transcribed mRNA. It can, in some instances, comprise up to about 400 adenine nucleotides. In some embodiments, the length of the 3'-poly(A) tail may be an essential element with respect to the stability of the individual mRNA.
  • a composition includes a stabilizing element.
  • Stabilizing elements may include for instance a histone stem-loop.
  • a stem-loop binding protein (SLBP) a 32 kDa protein has been identified. It is associated with the histone stem-loop at the 3'-end of the histone messages in both the nucleus and the cytoplasm. Its expression level is regulated by the cell cycle; it peaks during the S-phase, when histone mRNA levels are also elevated. The protein has been shown to be essential for efficient 3'-end processing of histone pre-mRNA by the U7 snRNP.
  • SLBP continues to be associated with the stem-loop after processing, and then stimulates the translation of mature histone mRNAs into histone proteins in the cytoplasm.
  • the RNA binding domain of SLBP is conserved through metazoa and protozoa; its binding to the histone stem-loop depends on the structure of the loop.
  • the minimum binding site includes at least three nucleotides 5’ and two nucleotides 3 relative to the stem-loop.
  • an mRNA includes a coding region, at least one histone stem- loop, and optionally, a poly(A) sequence or polyadenylation signal.
  • the poly(A) sequence or polyadenylation signal generally should enhance the expression level of the encoded protein.
  • the encoded protein in some embodiments, is not a histone protein, a reporter protein (e.g. Luciferase, GFP, EGFP, b-Galactosidase, EGFP), or a marker or selection protein (e.g. alpha- Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT)).
  • a reporter protein e.g. Luciferase, GFP, EGFP, b-Galactosidase, EGFP
  • a marker or selection protein e.g. alpha- Globin, Galactokinase and Xanthine:guanine phosphoribos
  • an mRNA includes the combination of a poly(A) sequence or polyadenylation signal and at least one histone stem- loop, even though both represent alternative mechanisms in nature, acts synergistically to increase the protein expression beyond the level observed with either of the individual elements.
  • the synergistic effect of the combination of poly(A) and at least one histone stem-loop does not depend on the order of the elements or the length of the poly(A) sequence.
  • an mRNA does not include a histone downstream element (HDE).
  • Histone downstream element includes a purine-rich polynucleotide stretch of approximately 15 to 20 nucleotides 3' of naturally occurring stem-loops, representing the binding site for the U7 snRNA, which is involved in processing of histone pre-mRNA into mature histone mRNA.
  • the nucleic acid does not include an intron.
  • an mRNA may or may not contain an enhancer and/or promoter sequence, which may be modified or unmodified or which may be activated or inactivated.
  • the histone stem-loop is generally derived from histone genes and includes an intramolecular base pairing of two neighbored partially or entirely reverse complementary sequences separated by a spacer, consisting of a short sequence, which forms the loop of the structure.
  • the unpaired loop region is typically unable to base pair with either of the stem loop elements. It occurs more often in RNA, as is a key component of many RNA secondary structures but may be present in single- stranded DNA as well. Stability of the stem-loop structure generally depends on the length, number of mismatches or bulges, and base composition of the paired region.
  • wobble base pairing non-Watson-Crick base pairing
  • the at least one histone stem-loop sequence comprises a length of 15 to 45 nucleotides.
  • an mRNA has one or more AU-rich sequences removed. These sequences, sometimes referred to as AURES are destabilizing sequences found in the 3’UTR.
  • the AURES may be removed from the RNA vaccines. Alternatively, the AURES may remain in the RNA vaccine.
  • a composition comprises an mRNA having an ORF that encodes a signal peptide fused to the coronavirus antigen.
  • Signal peptides comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway.
  • the signal peptide of a nascent precursor protein pre -protein
  • ER endoplasmic reticulum
  • ER processing produces mature proteins, wherein the signal peptide is cleaved from precursor proteins, typically by a ER-resident signal peptidase of the host cell, or they remain uncleaved and function as a membrane anchor.
  • a signal peptide may also facilitate the targeting of the protein to the cell membrane.
  • a signal peptide may have a length of 15-60 amino acids.
  • a signal peptide may have a length of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 amino acids.
  • a signal peptide has a length of 20-60, 25-60, 30-60, 35- 60, 40-60, 45- 60, 50-60, 55-60, 15-55, 20-55, 25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50, 35-50, 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40, 20- 40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30, 25-30, 15-25, 20-25, or 15-20 amino acids.
  • an ORF encoding an antigen of the disclosure is codon optimized. Codon optimization methods are known in the art. For example, an ORF of any one or more of the sequences provided herein may be codon optimized. Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce secondary structures; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove/add post translation modification sites in encoded protein (e.g., glycosylation sites); add, remove or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of the protein to fold properly; or reduce or eliminate problem secondary structures within the polynucleotide.
  • Codon optimization may be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce
  • Codon optimization tools, algorithms and services are known in the art - non limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park CA) and/or proprietary methods.
  • the open reading frame (ORF) sequence is optimized using optimization algorithms.
  • a codon optimized sequence shares less than 95% sequence identity to a naturally-occurring or wild-type sequence ORF (e.g., a naturally-occurring or wild- type mRNA sequence encoding a coronavirus antigen). In some embodiments, a codon optimized sequence shares less than 90% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen).
  • a codon optimized sequence shares less than 85% sequence identity to a naturally -occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen). In some embodiments, a codon optimized sequence shares less than 80% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen).
  • a codon optimized sequence shares less than 75% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen).
  • a codon optimized sequence shares between 65% and 85% (e.g., between about 67% and about 85% or between about 67% and about 80%) sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen). In some embodiments, a codon optimized sequence shares between 65% and 75% or about 80% sequence identity to a naturally-occurring or wild- type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a coronavirus antigen).
  • a codon-optimized sequence encodes an antigen that is as immunogenic as, or more immunogenic than (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 100%, or at least 200% more), than a coronavirus antigen encoded by a non-codon-optimized sequence.
  • the modified mRNAs When transfected into mammalian host cells, the modified mRNAs have a stability of between 12-18 hours, or greater than 18 hours, e.g., 24, 36, 48, 60, 72, or greater than 72 hours and are capable of being expressed by the mammalian host cells.
  • a codon optimized RNA may be one in which the levels of G/C are enhanced.
  • the G/C-content of nucleic acid molecules may influence the stability of the RNA.
  • RNA having an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than mRNA containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides.
  • WO02/098443 discloses a pharmaceutical composition containing an mRNA stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by substituting existing codons for those that promote greater RNA stability without changing the resulting amino acid. The approach is limited to coding regions of the RNA.
  • an mRNA is not chemically modified and comprises the standard ribonucleotides consisting of adenosine, guanosine, cytosine and uridine.
  • nucleotides and nucleosides of the present disclosure comprise standard nucleoside residues such as those present in transcribed RNA (e.g. A, G, C, or U).
  • nucleotides and nucleosides of the present disclosure comprise standard deoxyribonucleosides such as those present in DNA (e.g. dA, dG, dC, or dT).
  • compositions of the present disclosure comprise, in some embodiments, an mRNA having an open reading frame encoding a coronavirus antigen, wherein the nucleic acid comprises nucleotides and/or nucleosides that can be standard (unmodified) or modified as is known in the art.
  • nucleotides and nucleosides of the present disclosure comprise modified nucleotides or nucleosides.
  • modified nucleotides and nucleosides can be naturally-occurring modified nucleotides and nucleosides or non-naturally occurring modified nucleotides and nucleosides.
  • modifications can include those at the sugar, backbone, or nucleobase portion of the nucleotide and/or nucleoside as are recognized in the art.
  • a naturally-occurring modified nucleotide or nucleotide of the disclosure is one as is generally known or recognized in the art.
  • Non-limiting examples of such naturally occurring modified nucleotides and nucleotides can be found, inter alia, in the widely recognized MODOMICS database.
  • a non-naturally occurring modified nucleotide or nucleoside of the disclosure is one as is generally known or recognized in the art.
  • Non-limiting examples of such non-naturally occurring modified nucleotides and nucleosides can be found, inter alia, in published US application Nos. PCT/US2012/058519; PCT/US2013/075177;
  • nucleic acids of the disclosure can comprise standard nucleotides and nucleosides, naturally- occurring nucleotides and nucleosides, non-naturally-occurring nucleotides and nucleosides, or any combination thereof.
  • Nucleic acids of the disclosure e.g., DNA nucleic acids and RNA nucleic acids, such as mRNA nucleic acids
  • Nucleic acids of the disclosure comprise various (more than one) different types of standard and/or modified nucleotides and nucleosides.
  • a particular region of a nucleic acid contains one, two or more (optionally different) types of standard and/or modified nucleotides and nucleosides.
  • a modified RNA nucleic acid e.g., a modified mRNA nucleic acid
  • introduced to a cell or organism exhibits reduced degradation in the cell or organism, respectively, relative to an unmodified nucleic acid comprising standard nucleotides and nucleosides.
  • a modified RNA nucleic acid (e.g., a modified mRNA nucleic acid), introduced into a cell or organism, may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response) relative to an unmodified nucleic acid comprising standard nucleotides and nucleosides.
  • Nucleic acids e.g., RNA nucleic acids, such as mRNA nucleic acids
  • Nucleic acids in some embodiments, comprise non-natural modified nucleotides that are introduced during synthesis or post-synthesis of the nucleic acids to achieve desired functions or properties.
  • the modifications may be present on internucleotide linkages, purine or pyrimidine bases, or sugars.
  • the modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of the regions of a nucleic acid may be chemically modified.
  • nucleic acid e.g., RNA nucleic acids, such as mRNA nucleic acids.
  • a “nucleoside” refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as “nucleobase”).
  • nucleotide refers to a nucleoside, including a phosphate group.
  • Modified nucleotides may by synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides.
  • Nucleic acids can comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages can be standard phosphodiester linkages, in which case the nucleic acids would comprise regions of nucleotides.
  • Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures, such as, for example, in those nucleic acids having at least one chemical modification.
  • non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of base/sugar or linker may be incorporated into nucleic acids of the present disclosure.
  • modified nucleobases in nucleic acids comprise 1 -methyl-pseudouridine (ih ⁇ y), 1 -ethyl-pseudouridine (b ⁇ y), 5-methoxy-uridine (mo5U), 5-methyl-cytidine (m5C), and/or pseudouridine (y).
  • modified nucleobases in nucleic acids comprise 5-methoxymethyl uridine, 5-methylthio uridine, 1-methoxymethyl pseudouridine, 5-methyl cytidine, and/or 5-methoxy cytidine.
  • the polyribonucleotide includes a combination of at least two (e.g., 2, 3, 4 or more) of any of the aforementioned modified nucleobases, including but not limited to chemical modifications.
  • an mRNA of the disclosure comprises 1 -methyl-pseudouridine (hi ⁇ y) substitutions at one or more or all uridine positions of the nucleic acid.
  • an mRNA of the disclosure comprises 1 -methyl-pseudouridine (ml ⁇
  • an mRNA of the disclosure comprises pseudouridine (y) substitutions at one or more or all uridine positions of the nucleic acid.
  • an mRNA of the disclosure comprises pseudouridine (y) substitutions at one or more or all uridine positions of the nucleic acid and 5-methyl cytidine substitutions at one or more or all cytidine positions of the nucleic acid.
  • an mRNA of the disclosure comprises uridine at one or more or all uridine positions of the nucleic acid.
  • mRNAs are uniformly modified (e.g., fully modified, modified throughout the entire sequence) for a particular modification.
  • a nucleic acid can be uniformly modified with 1 -methyl-pseudouridine, meaning that all uridine residues in the mRNA sequence are replaced with 1 -methyl-pseudouridine.
  • a nucleic acid can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as those set forth above.
  • nucleic acids of the present disclosure may be partially or fully modified along the entire length of the molecule.
  • one or more or all or a given type of nucleotide e.g., purine or pyrimidine, or any one or more or all of A, G, U, C
  • nucleotides X in a nucleic acid of the present disclosure are modified nucleotides, wherein X may be any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.
  • the nucleic acid may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to
  • the mRNAs may contain at a minimum 1% and at maximum 100% modified nucleotides, or any intervening percentage, such as at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides.
  • the nucleic acids may contain a modified pyrimidine such as a modified uracil or cytosine.
  • At least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in the nucleic acid is replaced with a modified uracil (e.g., a 5-substituted uracil).
  • the modified uracil can be replaced by a compound having a single unique structure or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).
  • cytosine in the nucleic acid is replaced with a modified cytosine (e.g., a 5-substituted cytosine).
  • the modified cytosine can be replaced by a compound having a single unique stmcture or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).
  • the mRNAs of the present disclosure may comprise one or more regions or parts which act or function as an untranslated region. Where mRNAs are designed to encode at least one antigen of interest, the nucleic may comprise one or more of these untranslated regions (UTRs). Wild-type untranslated regions of a nucleic acid are transcribed but not translated. In mRNA, the 5' UTR starts at the transcription start site and continues to the start codon but does not include the start codon; whereas, the 3 ' UTR starts immediately following the stop codon and continues until the transcriptional termination signal. There is growing body of evidence about the regulatory roles played by the UTRs in terms of stability of the nucleic acid molecule and translation.
  • the regulatory features of a UTR can be incorporated into the polynucleotides of the present disclosure to, among other things, enhance the stability of the molecule.
  • the specific features can also be incorporated to ensure controlled down-regulation of the transcript in case they are misdirected to undesired organs sites.
  • a variety of 5’UTR and 3’UTR sequences are known and available in the art.
  • a 5' UTR is region of an mRNA that is directly upstream (5 1 ) from the start codon (the first codon of an mRNA transcript translated by a ribosome).
  • a 5' UTR does not encode a protein (is non-coding).
  • Natural 5 UTRs have features that play roles in translation initiation. They harbor signatures like Kozak sequences which are commonly known to be involved in the process by which the ribosome initiates translation of many genes.
  • Kozak sequences have the consensus CCR(A/G)CCAUGG (SEQ ID NO: 128), where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), which is followed by another 'G'.5UTR also have been known to form secondary structures which are involved in elongation factor binding.
  • a 5’ UTR is a heterologous UTR, i.e., is a UTR found in nature associated with a different ORF.
  • a 5’ UTR is a synthetic UTR, i.e., does not occur in nature.
  • Synthetic UTRs include UTRs that have been mutated to improve their properties, e.g., which increase gene expression as well as those which are completely synthetic.
  • Exemplary 5’ UTRs include Xenopus or human derived a-globin or b- globin (8278063; 9012219), human cytochrome b-245 a polypeptide, and hydroxysteroid (17b) dehydrogenase, and Tobacco etch virus (US8278063, 9012219).
  • CMV immediate-early 1 (IE1) gene (US20140206753, WO2013/185069), the sequence GGGAUCCUACC (SEQ ID NO: 129) (WO2014144196) may also be used.
  • 5' UTR of a TOP gene is a 5' UTR of a TOP gene lacking the 5' TOP motif (the oligopyrimidine tract) (e.g., WO/2015101414, W02015101415, WO/2015/062738, WO2015024667, WO2015024667; 5' UTR element derived from ribosomal protein Large 32 (L32) gene (WO/2015101414, W02015101415, WO/2015/062738), 5' UTR element derived from the 5'UTR of an hydroxysteroid (17-b) dehydrogenase 4 gene (HSD17B4) (WO2015024667), or a 5' UTR element derived from the 5' UTR of ATP5A1 (WO2015024667) can be used.
  • an internal ribosome entry site is used instead of a 5' UTR.
  • a 5' UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 131 and SEQ ID NO: 2.
  • a 3' UTR is region of an mRNA that is directly downstream (3 1 ) from the stop codon (the codon of an mRNA transcript that signals a termination of translation).
  • a 3' UTR does not encode a protein (is non-coding).
  • Natural or wild type 3' UTRs are known to have stretches of adenosines and uridines embedded in them. These AU rich signatures are particularly prevalent in genes with high rates of turnover. Based on their sequence features and functional properties, the AU rich elements (AREs) can be separated into three classes (Chen et al, 1995): Class I AREs contain several dispersed copies of an AUUUA motif within U-rich regions. C-Myc and MyoD contain class I AREs.
  • Class II AREs possess two or more overlapping UUAUUUA(U/A)(U/A) (SEQ ID NO: 130) nonamers. Molecules containing this type of AREs include GM-CSF and TNF-a. Class III ARES are less well defined. These U rich regions do not contain an AUUUA motif. c-Iun and Myogenin are two well-studied examples of this class.
  • HuR binds to AREs of all the three classes. Engineering the HuR specific binding sites into the 3' UTR of nucleic acid molecules will lead to HuR binding and thus, stabilization of the message in vivo.
  • AREs 3 ' UTR AU rich elements
  • nucleic acids e.g., RNA
  • AREs can be used to modulate the stability of nucleic acids (e.g., RNA) of the disclosure.
  • nucleic acids e.g., RNA
  • one or more copies of an ARE can be introduced to make nucleic acids of the disclosure less stable and thereby curtail translation and decrease production of the resultant protein.
  • AREs can be identified and removed or mutated to increase the intracellular stability and thus increase translation and production of the resultant protein.
  • Transfection experiments can be conducted in relevant cell lines, using nucleic acids of the disclosure and protein production can be assayed at various time points post-transfection. For example, cells can be transfected with different ARE-engineering molecules and by using an ELISA kit to the relevant protein and assaying protein produced at 6 hour, 12 hour, 24 hour, 48 hour, and 7 days post-transfection.
  • 3' UTRs may be heterologous or synthetic.
  • globin UTRs including Xenopus b-globin UTRs and human b-globin UTRs are known in the art (8278063, 9012219, US20110086907).
  • a modified b-globin construct with enhanced stability in some cell types by cloning two sequential human b-globin 3’UTRs head to tail has been developed and is well known in the art (US2012/0195936, WO2014/071963).
  • a2-globin, al-globin, UTRs and mutants thereof are also known in the art (W 02015101415, WO2015024667).
  • 3' UTRs described in the mRNA constructs in the non-patent literature include CYBA (Ferizi et al., 2015) and albumin (Thess et al., 2015).
  • Other exemplary 3' UTRs include that of bovine or human growth hormone (wild type or modified) (WO2013/185069, US20140206753, WO2014152774), rabbit b globin and hepatitis B virus (HBV), a-globin 3' UTR and Viral VEEV 3’ UTR sequences are also known in the art.
  • the sequence UUUGAAUU (WO2014144196) is used.
  • 3' UTRs of human and mouse ribosomal protein are used.
  • Other examples include rps9 3’UTR (W02015101414), FIG4 (W02015101415), and human albumin 7 (W02015101415).
  • a 3 1 UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 132 and SEQ ID NO: 4.
  • 5’UTRs that are heterologous or synthetic may be used with any desired 3’ UTR sequence.
  • a heterologous 5’UTR may be used with a synthetic 3’UTR with a heterologous 3” UTR.
  • Non-UTR sequences may also be used as regions or subregions within a nucleic acid.
  • introns or portions of introns sequences may be incorporated into regions of nucleic acid of the disclosure. Incorporation of intronic sequences may increase protein production as well as nucleic acid levels.
  • the ORF may be flanked by a 5' UTR which may contain a strong Kozak translational initiation signal and/or a 3' UTR which may include an oligo(dT) sequence for templated addition of a poly-A tail.
  • 5' UTR may comprise a first polynucleotide fragment and a second polynucleotide fragment from the same and/or different genes such as the 5' UTRs described in US Patent Application Publication No.20100293625 and PCT/US2014/069155, herein incorporated by reference in its entirety.
  • any UTR from any gene may be incorporated into the regions of a nucleic acid.
  • multiple wild-type UTRs of any known gene may be utilized. It is also within the scope of the present disclosure to provide artificial UTRs which are not variants of wild type regions. These UTRs or portions thereof may be placed in the same orientation as in the transcript from which they were selected or may be altered in orientation or location. Hence a 5' or 3' UTR may be inverted, shortened, lengthened, made with one or more other 5 r UTRs or 3' UTRs.
  • the term “altered” as it relates to a UTR sequence means that the UTR has been changed in some way in relation to a reference sequence.
  • a 3' UTR or 5' UTR may be altered relative to a wild-type or native UTR by the change in orientation or location as taught above or may be altered by the inclusion of additional nucleotides, deletion of nucleotides, swapping or transposition of nucleotides. Any of these changes producing an “altered” UTR (whether 3' or 5') comprise a variant UTR.
  • a double, triple or quadruple UTR such as a 5' UTR or 3' UTR may be used.
  • a “double” UTR is one in which two copies of the same UTR are encoded either in series or substantially in series.
  • a double beta-globin 3' UTR may be used as described in US Patent publication 20100129877, the contents of which are incorporated herein by reference in its entirety.
  • patterned UTRs are those UTRs which reflect a repeating or alternating pattern, such as ABABAB or AABBAABBAABB or ABCABCABC or variants thereof repeated once, twice, or more than 3 times. In these patterns, each letter, A, B, or C represent a different UTR at the nucleotide level.
  • flanking regions are selected from a family of transcripts whose proteins share a common function, structure, feature or property.
  • polypeptides of interest may belong to a family of proteins which are expressed in a particular cell, tissue or at some time during development.
  • the UTRs from any of these genes may be swapped for any other UTR of the same or different family of proteins to create a new polynucleotide.
  • a “family of proteins” is used in the broadest sense to refer to a group of two or more polypeptides of interest which share at least one function, structure, feature, localization, origin, or expression pattern.
  • the untranslated region may also include translation enhancer elements (TEE).
  • TEE translation enhancer elements
  • the TEE may include those described in US Application No.20090226470, herein incorporated by reference in its entirety, and those known in the art.
  • RNA cDNA encoding the polynucleotides described herein may be transcribed using an in vitro transcription (IVT) system.
  • IVT in vitro transcription
  • In vitro transcription of RNA is known in the art and is described in International Publication WO 2014/152027, which is incorporated by reference herein in its entirety.
  • the RNA of the present disclosure is prepared in accordance with any one or more of the methods described in WO 2018/053209 and WO 2019/036682, each of which is incorporated by reference herein.
  • the RNA transcript is generated using a non-amplified, linearized DNA template in an in vitro transcription reaction to generate the RNA transcript.
  • the template DNA is isolated DNA.
  • the template DNA is cDNA.
  • the cDNA is formed by reverse transcription of an mRNA, for example, but not limited to coronavirus mRNA.
  • cells e.g., bacterial cells, e.g., E. coli, e.g., DH-1 cells are transfected with the plasmid DNA template.
  • the transfected cells are cultured to replicate the plasmid DNA which is then isolated and purified.
  • the DNA template includes an RNA polymerase promoter, e.g., a T7 promoter located 5 ' to and operably linked to the gene of interest.
  • an in vitro transcription template encodes a 5' untranslated (UTR) region, contains an open reading frame, and encodes a 3' UTR and a poly(A) tail.
  • UTR 5' untranslated
  • poly(A) tail encodes a 3' UTR and a poly(A) tail.
  • the particular nucleic acid sequence composition and length of an in vitro transcription template will depend on the mRNA encoded by the template.
  • a “5' untranslated region” refers to a region of an mRNA that is directly upstream (i.e., 5') from the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide.
  • the 5’ UTR may comprise a promoter sequence. Such promoter sequences are known in the art. It should be understood that such promoter sequences will not be present in a vaccine of the disclosure.
  • a “3' untranslated region” refers to a region of an mRNA that is directly downstream (i.e., 3') from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide.
  • An “open reading frame” is a continuous stretch of DNA beginning with a start codon (e.g., methionine (ATG)), and ending with a stop codon (e.g., TAA, TAG or TGA) and encodes a polypeptide.
  • a start codon e.g., methionine (ATG)
  • a stop codon e.g., TAA, TAG or TGA
  • a “poly(A) tail” is a region of mRNA that is downstream, e.g., directly downstream (i.e., 3'), from the 3' UTR that contains multiple, consecutive adenosine monophosphates.
  • a poly(A) tail may contain 10 to 300 adenosine monophosphates.
  • a poly(A) tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210,
  • a poly(A) tail contains 50 to 250 adenosine monophosphates.
  • the poly(A) tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, and/or export of the mRNA from the nucleus and translation.
  • a nucleic acid includes 200 to 3,000 nucleotides.
  • a nucleic acid may include 200 to 500, 200 to 1000, 200 to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to 3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to 3000 nucleotides).
  • An in vitro transcription system typically comprises a transcription buffer, nucleotide triphosphates (NTPs), an RNase inhibitor and a polymerase.
  • the NTPs may be manufactured in house, may be selected from a supplier, or may be synthesized as described herein.
  • the NTPs may be selected from, but are not limited to, those described herein including natural and unnatural (modified) NTPs.
  • RNA polymerases or variants may be used in the method of the present disclosure.
  • the polymerase may be selected from, but is not limited to, a phage RNA polymerase, e.g., a T7 RNA polymerase, a T3 RNA polymerase, a SP6 RNA polymerase, and/or mutant polymerases such as, but not limited to, polymerases able to incorporate modified nucleic acids and/or modified nucleotides, including chemically modified nucleic acids and/or nucleotides. Some embodiments exclude the use of DNase.
  • the RNA transcript is capped via enzymatic capping.
  • the RNA comprises 5' terminal cap, for example, 7mG(5’)ppp(5’)NlmpNp.
  • Solid-phase chemical synthesis Nucleic acids the present disclosure may be manufactured in whole or in part using solid phase techniques.
  • Solid-phase chemical synthesis of nucleic acids is an automated method wherein molecules are immobilized on a solid support and synthesized step by step in a reactant solution. Solid-phase synthesis is useful in site-specific introduction of chemical modifications in the nucleic acid sequences.
  • DNA or RNA ligases promote intermolecular ligation of the 5’ and 3’ ends of polynucleotide chains through the formation of a phosphodiester bond.
  • Nucleic acids such as chimeric polynucleotides and/or circular nucleic acids may be prepared by ligation of one or more regions or subregions. DNA fragments can be joined by a ligase catalyzed reaction to create recombinant DNA with different functions. Two oligodeoxynucleotides, one with a 5’ phosphoryl group and another with a free 3’ hydroxyl group, serve as substrates for a DNA ligase.
  • nucleic acid clean-up may include, but is not limited to, nucleic acid clean-up, quality assurance and quality control. Clean-up may be performed by methods known in the arts such as, but not limited to, AGENCOURT® beads (Beckman Coulter Genomics, Danvers, MA), poly-T beads, LNATM oligo-T capture probes (EXIQON® Inc, Vedbaek, Denmark) or HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC-HPLC).
  • AGENCOURT® beads Beckman Coulter Genomics, Danvers, MA
  • poly-T beads poly-T beads
  • LNATM oligo-T capture probes EXIQON® Inc, Vedbaek, Denmark
  • HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (
  • purified when used in relation to a nucleic acid such as a “purified nucleic acid” refers to one that is separated from at least one contaminant.
  • a “contaminant” is any substance that makes another unfit, impure or inferior.
  • a purified nucleic acid e.g., DNA and RNA
  • a purified nucleic acid is present in a form or setting different from that in which it is found in nature, or a form or setting different from that which existed prior to subjecting it to a treatment or purification method.
  • a quality assurance and/or quality control check may be conducted using methods such as, but not limited to, gel electrophoresis, UV absorbance, or analytical HPLC.
  • the nucleic acids may be sequenced by methods including, but not limited to reverse-transcriptase-PCR.
  • the nucleic acids of the present disclosure may be quantified in exosomes or when derived from one or more bodily fluid.
  • Bodily fluids include peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheo alveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre -ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood.
  • CSF cerebrospinal
  • exosomes may be retrieved from an organ selected from the group consisting of lung, heart, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colon, breast, prostate, brain, esophagus, liver, and placenta.
  • Assays may be performed using construct specific probes, cytometry, qRT-PCR, real time PCR, PCR, flow cytometry, electrophoresis, mass spectrometry, or combinations thereof while the exosomes may be isolated using immunohistochemical methods such as enzyme linked immunosorbent assay (ELISA) methods. Exosomes may also be isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
  • immunohistochemical methods such as enzyme linked immunosorbent assay (ELISA) methods.
  • Exosomes may also be isolated by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
  • nucleic acids of the present disclosure in some embodiments, differ from the endogenous forms due to the structural or chemical modifications.
  • the nucleic acid may be quantified using methods such as, but not limited to, ultraviolet visible spectroscopy (UV/Vis).
  • UV/Vis ultraviolet visible spectroscopy
  • a non-limiting example of a UV/Vis spectrometer is a NANODROP® spectrometer (ThermoFisher, Waltham, MA).
  • the quantified nucleic acid may be analyzed in order to determine if the nucleic acid may be of proper size, check that no degradation of the nucleic acid has occurred.
  • Degradation of the nucleic acid may be checked by methods such as, but not limited to, agarose gel electrophoresis, HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC- HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE) and capillary gel electrophoresis (CGE).
  • HPLC based purification methods such as, but not limited to, strong anion exchange HPLC, weak anion exchange HPLC, reverse phase HPLC (RP-HPLC), and hydrophobic interaction HPLC (HIC- HPLC), liquid chromatography-mass spectrometry (LCMS), capillary electrophoresis (CE) and capillary gel electrophoresis (CGE).
  • LNPs Lipid Nanoparticles
  • the mRNA of the disclosure is formulated in a lipid nanoparticle (LNP).
  • LNP lipid nanoparticle
  • Lipid nanoparticles typically comprise ionizable cationic lipid, non-cationic lipid, sterol and PEG lipid components along with the nucleic acid cargo of interest.
  • the lipid nanoparticles of the disclosure can be generated using components, compositions, and methods as are generally known in the art, see for example PCT/US2016/052352; PCT/US2016/068300; PCT/US2017/037551 ; PCT/US2015/027400; PCT/US2016/047406; PCT/US2016000129; PCT/US2016/014280; PCT/US2016/014280; PCT/US2017/038426; PCT/US2014/027077; PCT/US2014/055394; PCT/US2016/52117; PCT/US2012/069610; PCT/US2017/027492; PCT/US2016/059575 and PCT/US2016/069491 all of which are incorporated by reference herein in their entirety.
  • Vaccines of the present disclosure are typically formulated in lipid nanoparticle.
  • the lipid nanoparticle comprises at least one ionizable cationic lipid, at least one non-cationic lipid, at least one sterol, and/or at least one polyethylene glycol (PEG)-modified lipid.
  • PEG polyethylene glycol
  • the lipid nanoparticle comprises 40-50 mol% ionizable lipid, optionally 45-50 mol%, for example, 45-46 mol%, 46-47 mol%, 47-48 mol%, 48-49 mol%, or 49-50 mol% for example about 45 mol%, 45.5 mol%, 46 mol%, 46.5 mol%, 47 mol%, 47.5 mol%, 48 mol , 48.5 mol%, 49 mol%, or 49.5 mol%.
  • the lipid nanoparticle comprises 30-45 mol% sterol, optionally 35- 40 mol%, for example, 30-31 mol%, 31-32 mol%, 32-33 mol%, 33-34 mol%, 35-35 mol%, 35- 36 mol%, 36-37 mol%, 38-38 mol%, 38-39 mol%, or 39-40 mol%.
  • the lipid nanoparticle comprises 5-15 mol% helper lipid, optionally 10-12 mol%, for example, 5-6 mol%, 6-7 mol%, 7-8 mol%, 8-9 mol%, 9-10 mol%, 10-11 mol%, 11-12 mol%, 12-13 mol%, 13-14 mol%, or 14-15 mol%.
  • the lipid nanoparticle comprises 1-5% PEG lipid, optionally 1-3 mol%, for example 1.5 to 2.5 mol%, 1-2 mol%, 2-3 mol%, 3-4 mol%, or 4-5 mol%.
  • the lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid.
  • the lipid nanoparticle may comprise 20-50 mol%, 20-40 mol%, 20-30 mol%, 30-60 mol%, 30-50 mol%, 30-40 mol%, 40-60 mol%, 40-50 mol%, or 50-60 mol% ionizable cationic lipid.
  • the lipid nanoparticle comprises 20 mol%, 30 mol%, 40 mol%, 50 mol%, or 60 mol% ionizable cationic lipid.
  • the lipid nanoparticle comprises 35 mol%, 36 mol%, 37 mol%, 38 mol%, 39 mol%, 40 mol%, 41 mol%, 42 mol%, 43 mol%, 44 mol%, 45 mol%, 46 mol%, 47 mol%, 48 mol%, 49 mol%, 50 mol%, 51 mol%, 52 mol%, 53 mol%, 54 mol%, or 55 mol% ionizable cationic lipid.
  • the lipid nanoparticle comprises 5-25 mol% non-cationic lipid.
  • the lipid nanoparticle may comprise 5-20 mol%, 5-15 mol%, 5-10 mol%, 10-25 mol%, 10-20 mol%, 10-25 mol%, 15-25 mol%, 15-20 mol%, or 20-25 mol% non-cationic lipid.
  • the lipid nanoparticle comprises 5 mol%, 10 mol%, 15 mol%, 20 mol%, or 25 mol% non-cationic lipid.
  • the lipid nanoparticle comprises 25-55 mol% sterol.
  • the lipid nanoparticle may comprise 25-50 mol%, 25-45 mol%, 25-40 mol%, 25-35 mol%, 25-30 mol%, 30-55 mol%, 30-50 mol%, 30-45 mol%, 30-40 mol%, 30-35 mol%, 35-55 mol%, 35-50 mol%, 35-45 mol%, 35-40 mol%, 40-55 mol%, 40-50 mol%, 40-45 mol%, 45-55 mol%, 45-50 mol%, or 50-55 mol% sterol.
  • the lipid nanoparticle comprises 25 mol%, 30 mol%, 35 mol%, 40 mol%, 45 mol%, 50 mol%, or 55 mol% sterol.
  • the lipid nanoparticle comprises 0.5-15 mol% PEG-modified lipid.
  • the lipid nanoparticle may comprise 0.5-10 mol , 0.5-5 mol%, 1-15 mol%, 1-10 mol%, 1-5 mol%, 2-15 mol%, 2-10 mol%, 2-5 mol%, 5-15 mol , 5-10 mol%, or 10-15 mol%.
  • the lipid nanoparticle comprises 0.5 mol%, 1 mol%, 2 mol%, 3 mol%, 4 mol%, 5 mol%, 6 mol%, 7 mol%, 8 mol%, 9 mol , 10 mol%, 11 mol%, 12 mol%, 13 mol%, 14 mol%, or 15 mol% PEG-modified lipid.
  • the lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid, 5-25 mol% non-cationic lipid, 25-55 mol% sterol, and 0.5-15 mol% PEG-modified lipid.
  • an ionizable cationic lipid of the disclosure comprises a compound of Formula (I): (I), or a salt or isomer thereof, wherein:
  • Ri is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, -R*YR”, -YR”, and -R”M’R’;
  • R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-,
  • R 7 is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;
  • Rs is selected from the group consisting of C 3-6 carbocycle and heterocycle
  • R9 is selected from the group consisting of H, CN, NO2, Ci-6 alkyl, -OR, -S(0) 2 R, -S(0) 2 N(R) 2 , C2-6 alkenyl, C3-6 carbocycle and heterocycle; each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R’ is independently selected from the group consisting of Cns alkyl, C2- I 8 alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl; each R* is independently selected from the group consisting of Ci- 12 alkyl and C2-12 alkenyl; each Y is independently a C3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.
  • a subset of compounds of Formula (I) includes those in which when R 4 is -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, or -CQ(R) 2 , then (i) Q is not -N(R) 2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.
  • another subset of compounds of Formula (I) includes those in which
  • Ri is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, -R*YR”, -YR”, and -R”M’R’;
  • R 2 and R 3 are independently selected from the group consisting of H, Ci- 14 alkyl, C 2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CFhl n Q, -(CH 2 ) n CHQR, -CHQR, -CQ(R) 2 , and unsubstituted Ci- 6 alkyl, where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -0(CH 2 )nN(R) 2 , -C(0)OR, -OC(0)R, -CX3, -CX 2 H, -CXH 2 , -CN, -C(0)N(R) 2 , -N(R)C(0)R, -N(R)S(0) 2 R, -N(R)C(0)N(R) 2 , -N(R)C(S)N(R) 2 , -CRN(R) 2 C(0)0R, -N(R)RS
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-,
  • R 7 is selected from the group consisting of C1-3 alkyl, C 2 -3 alkenyl, and H;
  • Rs is selected from the group consisting of C 3-6 carbocycle and heterocycle
  • R 9 is selected from the group consisting of H, CN, N0 2 , Ci- 6 alkyl, -OR, -S(0) 2 R, -S(0) 2 N(R) 2 , C 2-6 alkenyl, C3-6 carbocycle and heterocycle; each R is independently selected from the group consisting of C1-3 alkyl, C 2 -3 alkenyl, and H; each R’ is independently selected from the group consisting of Cns alkyl, C 2-i s alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl; each R* is independently selected from the group consisting of Ci-i 2 alkyl and C 2-i2 alkenyl; each Y is independently a C3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof
  • another subset of compounds of Formula (I) includes those in which Ri is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, -R*YR”, -YR”, and -R”M’R’;
  • R2 and R3 are independently selected from the group consisting of H, Ci-14 alkyl, C2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
  • R 4 is selected from the group consisting of a C 3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, -CQ(R) 2 , and unsubstituted Ci- 6 alkyl, where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, -OR, -0(CH 2 )nN(R) 2 , -C(0)OR, -OC(0)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -C(0)N(R) 2 ,
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-,
  • R 7 is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;
  • Rs is selected from the group consisting of C 3-6 carbocycle and heterocycle
  • R 9 is selected from the group consisting of H, CN, NO 2 , Ci- 6 alkyl, -OR, -S(0) 2 R, -S(0) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle; each R is independently selected from the group consisting of C1-3 alkyl, C 2-3 alkenyl, and H; each R’ is independently selected from the group consisting of C1-18 alkyl, C2-18 alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl; each R* is independently selected from the group consisting of Ci- 12 alkyl and C 2-12 alkenyl; each Y is independently a C 3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
  • another subset of compounds of Formula (I) includes those in which
  • Ri is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, -R*YR”, -YR”, and -R”M’R’;
  • R2 and R3 are independently selected from the group consisting of H, Ci-14 alkyl, C2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
  • R 4 is selected from the group consisting of a C3-6 carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, -CQ(R) 2 , and unsubstituted Ci- 6 alkyl, where Q is selected from a C3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, -OR, -0(CH 2 )nN(R) 2 , -C(0)OR, -OC(0)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -C(0)N(R) 2 ,
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-, -N(R’)C(0)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(0)(0R’)0-, -S(0) 2 -, -S-S-, an aryl group, and a heteroaryl group;
  • R 7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
  • Rs is selected from the group consisting of C 3-6 carbocycle and heterocycle
  • R 9 is selected from the group consisting of H, CN, NO2, Ci- 6 alkyl, -OR, -S(0) 2 R, -S(0) 2 N(R) 2 , C2-6 alkenyl, C3-6 carbocycle and heterocycle; each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R’ is independently selected from the group consisting of C MS alkyl, C2-18 alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl; each R* is independently selected from the group consisting of Ci-12 alkyl and C2-12 alkenyl; each Y is independently a C3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
  • another subset of compounds of Formula (I) includes those in which
  • Ri is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, -R* YR”, -YR”, and -R”M’R’;
  • R2 and R3 are independently selected from the group consisting of H, C2-14 alkyl, C2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
  • R4 is -(CFhlnQ or -(CFhlnCHQR, where Q is -N(R)2, and n is selected from 3, 4, and 5; each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R 6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-,
  • R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H; each R’ is independently selected from the group consisting of CMS alkyl, C2-18 alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl; each R* is independently selected from the group consisting of Ci-12 alkyl and Ci-12 alkenyl; each Y is independently a C 3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
  • another subset of compounds of Formula (I) includes those in which
  • Ri is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, -R*YR”, -YR”, and -R”M’R’;
  • R2 and R3 are independently selected from the group consisting of Ci-14 alkyl, C2-14 alkenyl, -R*YR”, -YR”, and -R*OR”, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
  • R 4 is selected from the group consisting of -(CFh) n Q, -(CFhl n CFIQR, -CF1QR, and -CQ(R) 2 , where Q is -N(R) 2 , and n is selected from 1, 2, 3, 4, and 5; each R5 is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H; each R 6 is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-,
  • R7 is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H; each R is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H; each R’ is independently selected from the group consisting of C MS alkyl, C2-18 alkenyl, -R*YR”, -YR”, and H; each R” is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl; each R* is independently selected from the group consisting of Ci-12 alkyl and Ci-12 alkenyl; each Y is independently a C 3-6 carbocycle; each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, or salts or isomers thereof.
  • a subset of compounds of Formula (I) includes those of Formula
  • Mi is a bond or M’
  • R.4 is unsubstituted C1-3 alkyl, or -(CH2) n Q, in which Q is OH, -NHC(S)N(R)2, -NHC(0)N(R)2, -N(R)C(0)R, -N(R)S(0) 2 R, -N(R)RS,
  • M and M’ are independently selected from -C(0)0-, -OC(O)-, -C(0)N(R’)-, -P(0)(0R’)0-, -S-S-, an aryl group, and a heteroaryl group; and R2 and R3 are independently selected from the group consisting of H, Ci-14 alkyl, and C2-14 alkenyl.
  • a subset of compounds of Formula (I) includes those of Formula
  • a subset of compounds of Formula (I) includes those of Formula (Da), (lib), (lie), or (He): or a salt or isomer thereof, wherein R4 is as described herein. In some embodiments, a subset of compounds of Formula (I) includes those of Formula
  • each of R2 and R3 may be independently selected from the group consisting of C5-14 alkyl and C5-14 alkenyl.
  • an ionizable cationic lipid of the disclosure comprises a compound having structure:
  • an ionizable cationic lipid of the disclosure comprises a compound having structure:
  • a non-cationic lipid of the disclosure comprises 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), l,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-gly cero- phosphocholine (DMPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl- sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (DSPC),
  • a PEG modified lipid of the disclosure comprises a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
  • the PEG-modified lipid is DMG-PEG, PEG-c- DOMG (also referred to as PEG-DOMG), PEG-DSG and/or PEG-DPG.
  • a sterol of the disclosure comprises cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha- tocopherol, and mixtures thereof.
  • a LNP of the disclosure comprises an ionizable cationic lipid of Compound 1, wherein the non-cationic lipid is DSPC, the structural lipid that is cholesterol, and the PEG lipid is DMG-PEG.
  • the lipid nanoparticle comprises 45 - 55 mole percent (mol%) ionizable cationic lipid.
  • lipid nanoparticle may comprise 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mol% ionizable cationic lipid.
  • the lipid nanoparticle comprises 5 - 15 mol%, 5 - 10 mol , or 10 - 15 mol% DSPC.
  • the lipid nanoparticle may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mol% DSPC.
  • the lipid nanoparticle comprises 35 - 40 mol% cholesterol.
  • the lipid nanoparticle may comprise 35, 35.5, 36, 36.5, 37, 37.5, 38, 38.5, 39, 39.5, or 40 mol% cholesterol.
  • the lipid nanoparticle comprises 1 - 2 mol%, 1 - 3 mol%, 1 - 4 mol%, or 1 - 5 mol% DMG-PEG.
  • the lipid nanoparticle may comprise 1, 1.5, 2, 2.5, 3, or 3.5 mol% DMG-PEG.
  • the lipid nanoparticle comprises 50 mol% ionizable cationic lipid, 10 mol% DSPC, 38.5 mol% cholesterol, and 1.5 mol% DMG-PEG.
  • the lipid nanoparticle comprises 49 mol% ionizable cationic lipid
  • the lipid nanoparticle comprises 49 mol% ionizable cationic lipid
  • the lipid nanoparticle comprises 48 mol% ionizable cationic lipid, 11 mol% DSPC, 38.5 mol% cholesterol, and 2.5 mol% DMG-PEG.
  • an LNP of the disclosure comprises an N:P ratio of from about 2:1 to about 30:1.
  • an LNP of the disclosure comprises an N:P ratio of about 6:1.
  • an LNP of the disclosure comprises an N:P ratio of about 3:1.
  • an LNP of the disclosure comprises a wt/wt ratio of the ionizable cationic lipid component to the RNA of from about 10:1 to about 100:1.
  • an LNP of the disclosure comprises a wt/wt ratio of the ionizable cationic lipid component to the RNA of about 20: 1.
  • an LNP of the disclosure comprises a wt/wt ratio of the ionizable cationic lipid component to the RNA of about 10:1.
  • an LNP of the disclosure has a mean diameter from about 50 nm to about 150 nm.
  • an LNP of the disclosure has a mean diameter from about 70 nm to about 120 nm.
  • compositions may include RNA or multiple RNAs encoding two or more antigens of the same or different species.
  • composition includes an mRNA or multiple mRNAs encoding two or more coronavirus antigens.
  • the RNA may encode 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more coronavirus antigens.
  • two or more different mRNA encoding antigens may be formulated in the same lipid nanoparticle.
  • two or more different RNA encoding antigens may be formulated in separate lipid nanoparticles (each RNA formulated in a single lipid nanoparticle).
  • the lipid nanoparticles may then be combined and administered as a single vaccine composition (e.g., comprising multiple RNA encoding multiple antigens) or may be administered separately.
  • compositions may include an mRNA or multiple RNAs encoding two or more antigens of the same or different viral strains.
  • combination vaccines that include RNA encoding one or more coronavims and one or more antigen(s) of a different organism.
  • the vaccines of the present disclosure may be combination vaccines that target one or more antigens of the same strain/species, or one or more antigens of different strains/species, e.g., antigens which induce immunity to organisms which are found in the same geographic areas where the risk of coronavirus infection is high or organisms to which an individual is likely to be exposed to when exposed to a coronavirus.
  • compositions e.g., pharmaceutical compositions
  • methods, kits and reagents for prevention or treatment of coronavirus in humans and other mammals, for example.
  • the compositions provided herein can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat a coronavirus infection.
  • the coronavirus vaccine containing RNA as described herein can be administered to a subject (e.g., a mammalian subject, such as a human subject), and the mRNAs are translated in vivo to produce an antigenic polypeptide (antigen).
  • a subject e.g., a mammalian subject, such as a human subject
  • the mRNAs are translated in vivo to produce an antigenic polypeptide (antigen).
  • an “effective amount” of a composition is based, at least in part, on the target tissue, target cell type, means of administration, physical characteristics of the RNA (e.g., length, nucleotide composition, and/or extent of modified nucleosides), other components of the vaccine, and other determinants, such as age, body weight, height, sex and general health of the subject.
  • an effective amount of a composition provides an induced or boosted immune response as a function of antigen production in the cells of the subject.
  • an effective amount of the composition containing mRNA having at least one chemical modifications are more efficient than a composition containing a corresponding unmodified polynucleotide encoding the same antigen or a peptide antigen.
  • Increased antigen production may be demonstrated by increased cell transfection (the percentage of cells transfected with the RNA vaccine), increased protein translation and/or expression from the polynucleotide, decreased nucleic acid degradation (as demonstrated, for example, by increased duration of protein translation from a modified polynucleotide), or altered antigen specific immune response of the host cell.
  • composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
  • a “pharmaceutically acceptable carrier,” after administered to or upon a subject, does not cause undesirable physiological effects.
  • the carrier in the pharmaceutical composition must be “acceptable” also in the sense that it is compatible with the active ingredient and can be capable of stabilizing it.
  • One or more solubilizing agents can be utilized as pharmaceutical carriers for delivery of an active agent.
  • a pharmaceutically acceptable carrier include, but are not limited to, biocompatible vehicles, adjuvants, additives, and diluents to achieve a composition usable as a dosage form.
  • examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, and sodium lauryl sulfate. Additional suitable pharmaceutical carriers and diluents, as well as pharmaceutical necessities for their use, are described in Remington's Pharmaceutical Sciences.
  • compositions comprising polynucleotides and their encoded polypeptides in accordance with the present disclosure may be used for treatment or prevention of a coronavirus infection.
  • a composition may be administered prophylactically or therapeutically as part of an active immunization scheme to healthy individuals or early in infection during the incubation phase or during active infection after onset of symptoms.
  • the amount of RNA provided to a cell, a tissue or a subject may be an amount effective for immune prophylaxis.
  • a composition may be administered with other prophylactic or therapeutic compounds.
  • a prophylactic or therapeutic compound may be an adjuvant or a booster.
  • a prophylactic composition such as a vaccine
  • the term “booster” refers to an extra administration of the prophylactic (vaccine) composition.
  • a booster or booster vaccine may be given after an earlier administration of the prophylactic composition.
  • the time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14
  • a composition may be administered intramuscularly, intranasally or intradermally, similarly to the administration of inactivated vaccines known in the art.
  • RNA vaccines may be utilized to treat and/or prevent a variety of infectious disease.
  • RNA vaccines have superior properties in that they produce much larger antibody titers, better neutralizing immunity, produce more durable immune responses, and/or produce responses earlier than commercially available vaccines.
  • compositions including RNA and/or complexes optionally in combination with one or more pharmaceutically acceptable excipients.
  • RNA may be formulated or administered alone or in conjunction with one or more other components.
  • a composition may comprise other components including, but not limited to, adjuvants.
  • a composition does not include an adjuvant (they are adjuvant free).
  • RNA may be formulated or administered in combination with one or more pharmaceutically-acceptable excipients.
  • vaccine compositions comprise at least one additional active substance, such as, for example, a therapeutically-active substance, a prophylactically- active substance, or a combination of both.
  • Vaccine compositions may be sterile, pyrogen-free or both sterile and pyrogen-free. General considerations in the formulation and/or manufacture of pharmaceutical agents, such as vaccine compositions, may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).
  • a composition is administered to humans, human patients or subjects.
  • active ingredient generally refers to the RNA vaccines or the polynucleotides contained therein, for example, mRNA encoding antigens.
  • Formulations of the vaccine compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • preparatory methods include the step of bringing the active ingredient (e.g., mRNA) into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.
  • compositions in accordance with the disclosure will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.
  • an mRNA is formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) permit the sustained or delayed release (e.g., from a depot formulation); (4) alter the biodistribution (e.g., target to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein (antigen) in vivo.
  • excipients can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with the RNA (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof.
  • compositions e.g., RNA vaccines
  • methods, kits and reagents for prevention and/or treatment of coronavirus infection in humans and other mammals can be used as therapeutic or prophylactic agents.
  • compositions are used to provide prophylactic protection from coronavirus infection.
  • compositions are used to treat a coronavims infection.
  • compositions are used in the priming of immune effector cells, for example, to activate peripheral blood mononuclear cells (PBMCs) ex vivo, which are then infused (re infused) into a subject.
  • PBMCs peripheral blood mononuclear cells
  • a subject may be any mammal, including non-human primate and human subjects.
  • a subject is a human subject.
  • a composition e.g., RNA a vaccine
  • a subject e.g., a mammalian subject, such as a human subject
  • RNA encoding the coronavirus antigen is expressed and translated in vivo to produce the antigen, which then stimulates an immune response in the subject.
  • Prophylactic protection from a coronavims can be achieved following administration of a composition of the present disclosure.
  • Immunizing compositions can be administered once, twice, three times, four times or more but it is likely sufficient to administer the vaccine once (optionally followed by a single booster). It is possible, although less desirable, to administer a composition to an infected individual to achieve a therapeutic response. Dosing may need to be adjusted accordingly.
  • a method involves administering to the subject a composition comprising a mRNA having an open reading frame encoding a coronavims antigen, thereby inducing in the subject an immune response specific to the coronavirus antigen, wherein anti-antigen antibody titer in the subject is increased following vaccination relative to anti-antigen antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the antigen.
  • An “anti-antigen antibody” is a semm antibody the binds specifically to the antigen.
  • a prophylactically effective dose is an effective dose that prevents infection with the virus at a clinically acceptable level.
  • the effective dose is a dose listed in a package insert for the vaccine.
  • a traditional vaccine refers to a vaccine other than the mRNA vaccines of the present disclosure.
  • a traditional vaccine includes, but is not limited, to live microorganism vaccines, killed microorganism vaccines, subunit vaccines, protein antigen vaccines, DNA vaccines, vims like particle (VLP) vaccines, etc.
  • a traditional vaccine is a vaccine that has achieved regulatory approval and/or is registered by a national drug regulatory body, for example the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA).
  • FDA Food and Drug Administration
  • EMA European Medicines Agency
  • the anti-antigen antibody titer in the subject is increased 1 log to 10 log following vaccination relative to anti-antigen antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the coronavirus or an unvaccinated subject. In some embodiments, the anti-antigen antibody titer in the subject is increased 1 log, 2 log, 3 log, 4 log, 5 log, or 10 log following vaccination relative to anti-antigen antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the coronavirus or an unvaccinated subject.
  • a method of eliciting an immune response in a subject against a coronavirus involves administering to the subject a composition comprising an mRNA comprising an open reading frame encoding a coronavirus antigen, thereby inducing in the subject an immune response specific to the coronavirus, wherein the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine against the coronavirus at 2 times to 100 times the dosage level relative to the composition.
  • the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at twice the dosage level relative to a composition of the present disclosure. In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at three times the dosage level relative to a composition of the present disclosure. In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 4 times, 5 times, 10 times, 50 times, or 100 times the dosage level relative to a composition of the present disclosure.
  • the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 10 times to 1000 times the dosage level relative to a composition of the present disclosure. In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 100 times to 1000 times the dosage level relative to a composition of the present disclosure.
  • the immune response is assessed by determining [protein] antibody titer in the subject.
  • the ability of serum or antibody from an immunized subject is tested for its ability to neutralize viral uptake or reduce coronavirus transformation of human B lymphocytes.
  • the ability to promote a robust T cell response(s) is measured using art recognized techniques.
  • the disclosure provide methods of eliciting an immune response in a subject against a coronavirus by administering to the subject composition comprising an mRNA having an open reading frame encoding a coronavirus antigen, thereby inducing in the subject an immune response specific to the coronavirus antigen, wherein the immune response in the subject is induced 2 days to 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the coronavirus.
  • the immune response in the subject is induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine at 2 times to 100 times the dosage level relative to a composition of the present disclosure.
  • the immune response in the subject is induced 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 5 weeks, or 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.
  • a composition may be administered by any route that results in a therapeutically effective outcome. These include, but are not limited, to intradermal, intramuscular, intranasal, and/or subcutaneous administration.
  • the present disclosure provides methods comprising administering RNA vaccines to a subject in need thereof. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like.
  • the RNA is typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the RNA may be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the effective amount of the RNA may be as low as 20 pg, administered for example as a single dose or as two 10 pg doses.
  • the effective amount is a total dose of 20 mg-300 mg or 25 mg-300 mg.
  • the effective amount may be a total dose of 20 m , 25 m , 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, or 300 mg.
  • the effective amount is a total dose of 20 mg.
  • the effective amount is a total dose of 25 pg. In some embodiments, the effective amount is a total dose of 50 mg. In some embodiments, the effective amount is a total dose of 75 mg. In some embodiments, the effective amount is a total dose of 100 mg. In some embodiments, the effective amount is a total dose of 150 mg. In some embodiments, the effective amount is a total dose of 200 mg. In some embodiments, the effective amount is a total dose of 250 pg. In some embodiments, the effective amount is a total dose of 300 mg.
  • RNA described herein can be formulated into a dosage form described herein, such as an intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, and subcutaneous).
  • injectable e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, and subcutaneous.
  • compositions e.g., RNA vaccines
  • the RNA is formulated in an effective amount to produce an antigen specific immune response in a subject (e.g., production of antibodies specific to a coronavirus antigen).
  • an effective amount is a dose of the RNA effective to produce an antigen- specific immune response.
  • methods of inducing an antigen- specific immune response in a subject are also provided herein.
  • an immune response to a vaccine or LNP of the present disclosure is the development in a subject of a humoral and/or a cellular immune response to a (one or more) coronavirus protein(s) present in the vaccine.
  • a “humoral” immune response refers to an immune response mediated by antibody molecules, including, e.g., secretory (IgA) or IgG molecules, while a “cellular” immune response is one mediated by T- lymphocytes (e.g., CD4+ helper and/or CD8+ T cells (e.g., CTLs) and/or other white blood cells.
  • T- lymphocytes e.g., CD4+ helper and/or CD8+ T cells (e.g., CTLs) and/or other white blood cells.
  • CTLs cytolytic T- cells
  • CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the surfaces of cells. CTLs help induce and promote the destruction of intracellular microbes or the lysis of cells infected with such microbes.
  • MHC major histocompatibility complex
  • Another aspect of cellular immunity involves and antigen- specific response by helper T-cells. Helper T-cells act to help stimulate the function and focus the activity nonspecific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface.
  • a cellular immune response also leads to the production of cytokines, chemokines, and other such molecules produced by activated T-cells and/or other white blood cells including those derived from CD4+ and CD8+ T-cells.
  • the antigen- specific immune response is characterized by measuring an anti-coronavirus antigen antibody titer produced in a subject administered a composition as provided herein.
  • An antibody titer is a measurement of the amount of antibodies within a subject, for example, antibodies that are specific to a particular antigen or epitope of an antigen.
  • Antibody titer is typically expressed as the inverse of the greatest dilution that provides a positive result.
  • Enzyme -linked immunosorbent assay is a common assay for determining antibody titers, for example.
  • a variety of serological tests can be used to measure antibody against encoded antigen of interest, for example, SAR-CoV-2 virus or SAR-CoV-2 viral antigen, e.g., SAR-CoV-2 spike or S protein, of domain thereof. These tests include the hemagglutination-inhibition test, complement fixation test, fluorescent antibody test, enzyme-linked immunosorbent assay (ELISA), and plaque reduction neutralization test (PRNT). Each of these tests measures different antibody activities.
  • a plaque reduction neutralization test, or PRNT is used as a serological correlate of protection. PRNT measures the biological parameter of in vitro virus neutralization and is the most serologically virus -specific test among certain classes of viruses, correlating well to serum levels of protection from virus infection.
  • the basic design of the PRNT allows for virus-antibody interaction to occur in a test tube or microtiter plate, and then measuring antibody effects on viral infectivity by plating the mixture on virus-susceptible cells, preferably cells of mammalian origin.
  • virus-susceptible cells preferably cells of mammalian origin.
  • the cells are overlaid with a semi-solid media that restricts spread of progeny virus.
  • Each virus that initiates a productive infection produces a localized area of infection (a plaque), that can be detected in a variety of ways. Plaques are counted and compared back to the starting concentration of virus to determine the percent reduction in total virus infectivity.
  • the serum sample being tested is usually subjected to serial dilutions prior to mixing with a standardized amount of vims.
  • the concentration of virus is held constant such that, when added to susceptible cells and overlaid with semi-solid media, individual plaques can be discerned and counted. In this way, PRNT end point titers can be calculated for each semm sample at any selected percent reduction of vims activity.
  • the serum sample dilution series for antibody titration should ideally start below the “seroprotective” threshold titer.
  • the “seroprotective” threshold titer remains unknown; but a seropositivity threshold of 1:10 can be considered a seroprotection threshold in certain embodiments.
  • PRNT end-point titers are expressed as the reciprocal of the last serum dilution showing the desired percent reduction in plaque counts.
  • the PRNT titer can be calculated based on a 50% or greater reduction in plaque counts (PRNT50).
  • PRNT50 titer is preferred over titers using higher cut-offs (e.g., PRNT90) for vaccine sera, providing more accurate results from the linear portion of the titration curve.
  • PRNT titers There are several ways to calculate PRNT titers. The simplest and most widely used way to calculate titers is to count plaques and report the titer as the reciprocal of the last serum dilution to show >50% reduction of the input plaque count as based on the back-titration of input plaques. Use of curve fitting methods from several serum dilutions may permit calculation of a more precise result. There are a variety of computer analysis programs available for this (e.g., SPSS or GraphPad Prism).
  • an antibody titer is used to assess whether a subject has had an infection or to determine whether immunizations are required. In some embodiments, an antibody titer is used to determine the strength of an autoimmune response, to determine whether a booster immunization is needed, to determine whether a previous vaccine was effective, and to identify any recent or prior infections. In accordance with the present disclosure, an antibody titer may be used to determine the strength of an immune response induced in a subject by a composition (e.g., RNA vaccine).
  • a composition e.g., RNA vaccine
  • an anti-coronavirus antigen antibody titer produced in a subject is increased by at least 1 log relative to a control.
  • anti-coronavirus antigen antibody titer produced in a subject may be increased by at least 1.5, at least 2, at least 2.5, or at least 3 log relative to a control.
  • the anti-coronavirus antigen antibody titer produced in the subject is increased by 1, 1.5, 2, 2.5 or 3 log relative to a control.
  • the anti-coronavirus antigen antibody titer produced in the subject is increased by 1-3 log relative to a control.
  • the anti-coronavirus antigen antibody titer produced in a subject may be increased by 1-1.5, 1-2, 1-2.5, 1-3, 1.5-2, 1.5-2.5, 1.5-3, 2-2.5, 2-3, or 2.5-3 log relative to a control.
  • the anti-coronavirus antigen antibody titer produced in a subject is increased at least 2 times relative to a control.
  • the anti-coronavirus antigen antibody titer produced in a subject may be increased at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times relative to a control.
  • the anti-coronavirus antigen antibody titer produced in the subject is increased 2, 3, 4, 5, 6, 7, 8, 9, or 10 times relative to a control.
  • the anti- coronavirus antigen antibody titer produced in a subject is increased 2-10 times relative to a control.
  • the anti-coronavirus antigen antibody titer produced in a subject may be increased 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 times relative to a control.
  • an antigen-specific immune response is measured as a ratio of geometric mean titer (GMT), referred to as a geometric mean ratio (GMR), of serum neutralizing antibody titers to coronavirus.
  • GTT geometric mean titer
  • a geometric mean titer (GMT) is the average antibody titer for a group of subjects calculated by multiplying all values and taking the nth root of the number, where n is the number of subjects with available data.
  • a control in some embodiments, is an anti-coronavirus antigen antibody titer produced in a subject who has not been administered a composition (e.g., RNA vaccine).
  • a control is an anti-coronavirus antigen antibody titer produced in a subject administered a recombinant or purified protein vaccine.
  • Recombinant protein vaccines typically include protein antigens that either have been produced in a heterologous expression system (e.g., bacteria or yeast) or purified from large amounts of the pathogenic organism.
  • the ability of a composition is measured in a murine model.
  • a composition may be administered to a murine model and the murine model assayed for induction of neutralizing antibody titers.
  • Viral challenge studies may also be used to assess the efficacy of a vaccine of the present disclosure.
  • a composition may be administered to a murine model, the murine model challenged with virus, and the murine model assayed for survival and/or immune response (e.g., neutralizing antibody response, T cell response (e.g., cytokine response)).
  • an effective amount of a composition is a dose that is reduced compared to the standard of care dose of a recombinant protein vaccine.
  • a “standard of care,” as provided herein, refers to a medical or psychological treatment guideline and can be general or specific. “Standard of care” specifies appropriate treatment based on scientific evidence and collaboration between medical professionals involved in the treatment of a given condition. It is the diagnostic and treatment process that a physician/ clinician should follow for a certain type of patient, illness or clinical circumstance.
  • a “standard of care dose,” as provided herein, refers to the dose of a recombinant or purified protein vaccine, or a live attenuated or inactivated vaccine, or a VLP vaccine, that a physician/clinician or other medical professional would administer to a subject to treat or prevent coronavirus infection or a related condition, while following the standard of care guideline for treating or preventing coronavirus infection or a related condition.
  • the anti-coronavirus antigen antibody titer produced in a subject administered an effective amount of a composition is equivalent to an anti-coronavirus antigen antibody titer produced in a control subject administered a standard of care dose of a recombinant or purified protein vaccine, or a live attenuated or inactivated vaccine, or a VLP vaccine.
  • Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1;201(11): 1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:
  • AR disease attack rate
  • vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1 ;201 ( 11 ) : 1607 -10).
  • Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial.
  • Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the ‘real-world’ outcomes of hospitalizations, ambulatory visits, or costs.
  • a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared.
  • Vaccine effectiveness may be expressed as a rate difference, with use of the odds ratio (OR) for developing infection despite vaccination:
  • efficacy of the composition is at least 60% relative to unvaccinated control subjects.
  • efficacy of the composition may be at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95%, at least 98%, or 100% relative to unvaccinated control subjects.
  • Sterilizing immunity refers to a unique immune status that prevents effective pathogen infection into the host.
  • the effective amount of a composition of the present disclosure is sufficient to provide sterilizing immunity in the subject for at least 1 year.
  • the effective amount of a composition of the present disclosure is sufficient to provide sterilizing immunity in the subject for at least 2 years, at least 3 years, at least 4 years, or at least 5 years.
  • the effective amount of a composition of the present disclosure is sufficient to provide sterilizing immunity in the subject at an at least 5-fold lower dose relative to control.
  • the effective amount may be sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower, 15-fold, or 20-fold lower dose relative to a control.
  • the effective amount of a composition of the present disclosure is sufficient to produce detectable levels of coronavirus antigen as measured in serum of the subject at 1-72 hours post administration.
  • An antibody titer is a measurement of the number of antibodies within a subject, for example, antibodies that are specific to a particular antigen (e.g., an anti-coronavirus antigen). Antibody titer is typically expressed as the inverse of the greatest dilution that provides a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers, for example.
  • ELISA Enzyme-linked immunosorbent assay
  • the effective amount of a composition of the present disclosure is sufficient to produce a 1,000-10,000 neutralizing antibody titer produced by neutralizing antibody against the coronavirus antigen as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount is sufficient to produce a 1,000-5,000 neutralizing antibody titer produced by neutralizing antibody against the coronavirus antigen as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount is sufficient to produce a 5,000-10,000 neutralizing antibody titer produced by neutralizing antibody against the coronavirus antigen as measured in serum of the subject at 1-72 hours post administration.
  • the neutralizing antibody titer is at least 100 NT50.
  • the neutralizing antibody titer may be at least 200, 300, 400, 500, 600, 700, 800, 900 or 1000 NT50.
  • the neutralizing antibody titer is at least 10,000 NT50.
  • the neutralizing antibody titer is at least 100 neutralizing units per milliliter (NU/mL).
  • the neutralizing antibody titer may be at least 200, 300, 400, 500, 600, 700, 800, 900 or 1000 NU/mL.
  • the neutralizing antibody titer is at least 10,000 NU/mL.
  • an anti-coronavirus antigen antibody titer produced in the subject is increased by at least 1 log relative to a control.
  • an anti-coronavirus antigen antibody titer produced in the subject may be increased by at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 log relative to a control.
  • an anti-coronavirus antigen antibody titer produced in the subject is increased at least 2 times relative to a control.
  • an anti-coronavirus antigen antibody titer produced in the subject is increased by at least 3, 4, 5, 6, 7, 8, 9 or 10 times relative to a control.
  • a geometric mean which is the nth root of the product of n numbers, is generally used to describe proportional growth.
  • Geometric mean in some embodiments, is used to characterize antibody titer produced in a subject.
  • a control may be, for example, an unvaccinated subject, or a subject administered a live attenuated viral vaccine, an inactivated viral vaccine, or a protein subunit vaccine.
  • a messenger ribonucleic acid comprising an open reading frame encoding a fusion protein comprising a receptor binding domain (RBD) of a SARS-CoV-2 Spike protein and a protein transmembrane domain.
  • fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77.
  • the open reading frame comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 76.
  • the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76.
  • a messenger ribonucleic acid comprising an open reading frame encoding a fusion protein comprising an amino (N)-terminal domain (NTD) of a SARS-CoV-2 Spike protein and a transmembrane domain.
  • transmembrane domain is an influenza hemagglutinin transmembrane domain.
  • the fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47.
  • mRNA of any one of the preceding paragraphs wherein the open reading frame comprises a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 46.
  • the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46.
  • a messenger ribonucleic acid comprising an open reading frame encoding a fusion protein comprising an amino (N)-terminal domain of a SARS-CoV-2 Spike protein linked to a receptor binding domain of a SARS-CoV-2 Spike protein.
  • the fusion protein comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 92.
  • the fusion protein comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 92.
  • the mRNA of paragraph 22, wherein the open reading frame comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 91.
  • RNA of any one of the preceding paragraphs further comprising a 5' untranslated region (UTR), optionally comprising the nucleotide sequence of SEQ ID NO: 131 or 2.
  • UTR 5' untranslated region
  • mRNA of any one of the preceding paragraphs further comprising a 3' untranslated region (UTR), optionally comprising the nucleotide sequence of SEQ ID NO: 132 or 4.
  • UTR 3' untranslated region
  • mRNA of any one of the preceding paragraphs further comprising a polyA tail, optionally having a length of about 100 nucleotides.
  • composition comprising the mRNA of any one of paragraphs 1-29.
  • composition comprising the mRNA of any one of paragraphs 1-8 and the mRNA of any one of paragraphs 9-16.
  • composition comprising the mRNA of any one of paragraphs 17-29.
  • a composition comprising:
  • mRNA messenger ribonucleic acid
  • RBD receptor binding domain
  • composition of paragraph 34, wherein the fusion protein of (a) comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 77.
  • composition of paragraph 35, wherein the fusion protein of (a) comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77.
  • composition of paragraph 36, wherein the fusion protein of (a) comprises the amino acid sequence of SEQ ID NO: 77.
  • composition of paragraph 38 wherein the open reading frame of (a) comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76.
  • composition of paragraph 39, wherein the open reading frame of (a) comprises the nucleotide sequence of SEQ ID NO: 76.
  • composition of any one of paragraphs 34-40, wherein the fusion protein of (b) comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 47.
  • composition of paragraph 41, wherein the fusion protein of (b) comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47.
  • composition of paragraph 42, wherein the fusion protein of (b) comprises the amino acid sequence of SEQ ID NO: 47.
  • composition of paragraph 44 wherein the open reading frame of (b) comprises a nucleotide sequence having at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46.
  • composition of paragraph 45 wherein the open reading frame of (b) comprises the nucleotide sequence of SEQ ID NO: 46.
  • composition of any one of paragraphs 30-47 further comprising a lipid nanoparticle.
  • composition of paragraph 51 wherein the mRNA of (a) and (b) are in the same lipid nanoparticle or wherein each of the mRNA of (a) and (b) is formulated in a separate nanoparticle, relative to each other.
  • lipid nanoparticle further comprises a polyethylene glycol (PEG)-modified lipid.
  • PEG polyethylene glycol
  • lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.
  • lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid, 5-25 mol% neutral lipid, 25-55 mol% sterol, and 0.5-15 mol% PEG-modified lipid.
  • lipid nanoparticle comprises:
  • a method comprising administering to a subject the mRNA or the composition of any one of the preceding paragraphs in an amount effective to induce in the subject a neutralizing antibody response against SARS-CoV-2.
  • a method comprising administering to a subject the mRNA or the composition of any one of the preceding paragraphs in an amount effective to induce in the subject a T cell immune response against SARS-CoV-2.
  • a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) that encodes a coronavirus antigen capable of inducing an immune response, such as a neutralizing antibody response, to a SARS-CoV-2, wherein the antigen comprises a protein fragment or a functional protein domain of a SARS-CoV-2, optionally wherein the RNA is formulated in a lipid nanoparticle.
  • ORF open reading frame
  • the mRNA of paragraph 67, wherein the antigen is a functional protein domain.
  • the protein domain is an N-terminal domain (NTD) of a SARS-CoV-2 Spike protein.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 47, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 47.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 46, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 46.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 62, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 62.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 61, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 61.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 77, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 77.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 76, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NOs: 76.
  • NTD-RBD fusion is linked to a transmembrane domain (TM), optionally an influenza hemagglutinin transmembrane domain, to form an NTD- RBD-TM protein.
  • TM transmembrane domain
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 92, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 92.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 91, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 91.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 107, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 107.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 106, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 106.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 59, 86, 89, 116, 119, or 122, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 59, 86, 89, 116, 119, or 122. 89.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 58, 85, 88, 115, 118, or 121, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 58, 85, 88, 115, 118, or 121.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 5, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 5.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 3, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 3.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 17, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 17.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 16, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 16.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 20, 23, 26, 29, 32 or 35, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 20, 23, 26, 29, 32, or 35.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 19, 22, 25, 28, 41, or 34, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 19, 22, 25, 28, 31, or 34.
  • the S2 subunit is from a SARS-CoV-2 S protein and in some embodiments wherein the S2 subunit comprises an open reading frame comprising a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 145, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NOs: 145.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 38, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 38.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 37, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 37.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 41, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 41.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 40, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 40.
  • the antigen further comprises a scaffold domain, optionally selected from ferritin, lumazine synthetase and a foldon.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 8 or 65, optionally wherein the antigen comprises the amino acid sequence of SEQ ID NO: 8 or 65.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of SEQ ID NO: 7 or 64, optionally wherein the open reading frame comprises the nucleotide sequence of SEQ ID NO: 7 or 64.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 11, 14, 68, or 71, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 11, 14, 68, or 71.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 10, 13, 67, or 70, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 10, 13, 67, or 70.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 44, 50, 74, 80, 83, 101, 104 or 113, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 44, 50, 74, 80, 83, 101, 104 or 113.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 43, 49, 73, 79, 82, 100, 103, or 112, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 43, 49, 73, 79, 82, 100, 103, or 112.
  • mRNA of any one of the preceding paragraphs wherein the antigen further comprising a trafficking signal, optionally selected from macrophage markers, optionally CD86, CD11B and/or VSVGct.
  • a trafficking signal optionally selected from macrophage markers, optionally CD86, CD11B and/or VSVGct.
  • the antigen comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of any one of SEQ ID NOs: 95, 98, or 110, optionally wherein the antigen comprises the amino acid sequence of any one of SEQ ID NOs: 95, 98, or 110.
  • the open reading frame comprises a nucleotide sequence having at least 70%, least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 94, 97, or 109, optionally wherein the open reading frame comprises the nucleotide sequence of any one of SEQ ID NOs: 94, 97, or 109.
  • lipid nanoparticle comprises a cationic lipid, optionally an ionizable cationic lipid, a neutral lipid, a sterol, and/or a polyethylene glycol (PEG)-modified lipid.
  • ionizable cationic lipid is heptadecan-9-yl 8 ((2 hydroxyethyl)(6 oxo 6-(undecyloxy)hexyl)amino)octanoate (Compound 1)
  • the neutral lipid is 1,2 distearoyl-sn-glycero-3-phosphocholine (DSPC)
  • the sterol is cholesterol
  • the PEG-modified lipid is 1,2 dimyristoyl-sn-glycerol, methoxypolyethyleneglycol (PEG2000 DMG).
  • lipid nanoparticle comprises 20-60 mol% ionizable cationic lipid, 5-25 mol% neutral lipid, 25-55 mol% sterol, and 0.5-15 mol% PEG-modified lipid.
  • lipid nanoparticle comprises:
  • a method comprising administering to a subject the mRNA of any one of the paragraphs 67-126 in an amount effective to induce in the subject a neutralizing antibody response against SARS-CoV-2.
  • a method comprising administering to a subject the mRNA of any one of the paragraphs 67-126 in an amount effective to induce in the subject a T cell immune response against SARS- CoV-2.
  • the mRNAs used in the present study were used to express key neutralizing domains of the SARS-CoV-2 coronavirus spike (S) protein and assess whether these neutralizing protein domains may be more efficient at inducing protective immunity when used individually or in combination as an immunogenic composition or vaccine to protect people from infection by the live and spreading natural virus.
  • the linear designs of the proteins encoded by the mRNAs are shown in FIG. 2.
  • the proteins all also contain a carboxy (C) terminal transmembrane domain (TM) derived from the hemagglutinin (HA) of influenza. Both the NTD and RBD are known to be sites for binding of antibodies that manifest neutralizing virus activity.
  • RBD in the case of SARS-CoV-2 is the receptor binding site of the spike protein and binds the angiotensin-converting enzyme 2 (ACE2).
  • ACE2 angiotensin-converting enzyme 2
  • SARS-CoV-2 Spike protein-specific IgG titers Table 17
  • SARS-CoV-2 RBD-specific IgG titers Table 18
  • SARS-CoV-2 NTD-specific IgG titers Table 19
  • Neutralization titers from serum of mice vaccinated with the 1 pg dose of RBD-TM and NTD-RBD-TM compositions and the 2 pg dose of the 50:50 mixture of NTD-TM and RBD-TM compositions were measured and the correlation between ELISA titers and neutralization titers was analyzed (FIG. 7).
  • the titers elicited by 1 mg dose of the NTD-RBD-TM composition or 2 mg of the 50:50 mixture of NTD-TM and RBD-TM compositions were greater than those elicited by the 1 mg dose of RBD-TM composition (Table 20).
  • Codon-optimized wild-type or D614G spike gene (Wuhan-Hu-1 strain; NC_045512.2) was cloned into pCAGGS vector.
  • BHK- 21/WI-2 cells were transfected with the spike expression plasmid and infected VSVAG-firefly- luciferase as previously described (Whitt, 2010).
  • A549-hACE2-TMPRSS2 cells were used as target cells for VSVAG-based SARS-CoV-2 pseudovirus neutralization assay.
  • Lentivirus encoding hACE2-P2A-TMPRSS2 was made to generate A549-hACE2-TMPRSS2 cells which were maintained in DMEM supplemented with 10% fetal bovine serum and 1 pg/mL puromycin.
  • A549-hACE2-TMPRSS2 cells were infected by pseudovirus for 1 hr at 37 Celsius. The inoculum virus or virus-antibody mix was removed after infection. 18 hr later, equal volume of One-Glo reagent (Promega; E6120) was added to culture medium for readout using BMG PHERastar-FS plate reader. The neutralization procedure and data analysis are same as mentioned above in the lentivirus-based pseudovirus neutralization assay. See Whitt, M.A. (2010). Journal of Virological Methods 169, 365-374.
  • the same doses of the mRNA vaccines described in Example 2 were again administered to mice as booster doses on Day 22 post- vaccination with the first dose.
  • the titers of antibodies generated after the booster dose to each ofRBD antigen, NTD antigen, wildtype (WT) Spike (S) protein and S2P protein (S protein having a double proline mutations to stabilize the prefusion conformation) were measured by ELISA from day 36 serum and shown below.
  • the 50:50 mixture of the two immunogenic compositions of RBD-TM and NTD-TM encoded by mRNA in an LNP were administered at 2 pg or 0.2 pg total mRNA to mice as a booster dose on day 22 and the titers were determined on day 36. See Table 21.
  • mice immunized with RBD-TM, NTD-TM, or the NTD-RBD-TM encoded by mRNA in an LNP indicated that two doses were superior at all doses tested in inducing antibodies that could recognize and bind to SARS-CoV-2 WT S protein.
  • the titers to SARS-CoV-2 S2P protein were determined by ELISA using the S2P as the antigen on the plate and are shown below in Table 22. Each of these immunogens induced much higher antibody titers when S2P was the antigen versus when WT S protein was the ELISA antigen. Compare Table 21 and Table 22.
  • the immunogen was the 50:50 mix of RBD-TM and NTD-TM encoded by mRNA in an LNP and the titers to WT S, RBD, NTD, and S2P were determined after one dose (day 21) and two doses (day 36). These results show dramatically increased titers when the immunogen is the combination of RBD-TM and NTD-TM in a 50:50 mix compared to the antibody titers induced by the individual antigens at the same doses.
  • the 50:50 mix induced good titers to the immunizing antigens, but surprisingly even better titers to the WT S protein and extremely higher titers to the S2P protein. See Table 23.
  • Table 24 shows the results of an immunization with each of RBD-TM and NTD-TM as mRNA encoding those antigens.
  • the geometric mean titers were measured for groups of 8 mice using the protein encoded by the mRNA immunogen as the antigen on the ELISA plate.
  • both immunogenic compositions induced high titers to the immunizing antigen when the antigen is administered as mRNA formulated in an LNP.
  • two doses produced superior antibody responses at all concentrations.
  • the 50:50 mix of these antigens induced about a 10-fold higher antibody response than when the antigens are administered singly. Compare Table 23 and Table 24.
  • the fusion protein comprising NTD linked to RBD and encoded by mRNA in an LNP was administered as an immunogenic composition to groups of 8 mice at 0.1 and 1 pg doses at days 1 and 21. See Table 25 below. Even the mRNA encoding the fusion protein version of NTD-RBD-
  • TM induced very good titers to the individual domains that were higher than when a single domain was the immunizing antigen.
  • the titers to the S2P protein were about 8-fold higher than the titers to WT S protein. See Table 25.
  • S1-666-TM encoded by mRNA is an antigen using the SI subdomain, specifically residues 1-666 of SARS-CoV-2 spike protein attached to a transmembrane domain.
  • the titers of antibodies generated after the booster dose to each of mRNA RBD, mRNA NTD, and mRNA wildtype (WT) Spike (S) protein (FIG. 1) were measured by ELISA from days 21 (pre-boost) and 36 (post boost) serum and shown below in Table 27
  • Results showed that 1 pg and 0.1 pg doses of mRNA RBD-TM, mRNA NTD-TM, mRNA NTD-RBD-TM compositions, and 50:50 mixtures containing 1 pg or 0.1 pg each of mRNA RBD-TM and mRNA NTD-TM compositions, elicited high ELISA titers towards SARS- CoV-2 Spike or SARS-CoV-2 S2P proteins.
  • compositions of NTD-RBD-TM, mRNA NTD-RBD-TM were administered to mice at the following doses: 0.1 pg and 1 pg.
  • a prime dose was administered on Day 1, and a boost dose was admini tered on Day 22.
  • S2P specific IgGl and IgG2a titers were assessed. See FIGs. 7A-7C.
  • the titer of IgG2a was higher than the amount of IgGl at both dose levels. See FIG. 7A.
  • To determine whether the T cell response is skewed toward either a Thl or a Th2 type of response we plotted the ration of IgG2a/IgGl at the day 36 timepoint.
  • the NTD-RBD-TM composition induces an antibody immune response that is cleanly within the Thl type of response. Th2 type response is disfavored in vaccine development because of an association with driving disease enhancement.
  • any of the mRNA sequences described herein may include a 5' UTR and/or a 3' UTR.
  • the UTR sequences may be selected from the following sequences, or other known UTR sequences may be used.
  • any of the mRNA constructs described herein may further comprise a poly (A) tail and/or cap (e.g., 7mG(5’)ppp(5’)NlmpNp).
  • RNAs and encoded antigen sequences described herein include a signal peptide and/or a peptide tag (e.g., C-terminal His tag), it should be understood that the indicated signal peptide and/or peptide tag may be substituted for a different signal peptide and/or peptide tag, or the signal peptide and/or peptide tag may be omitted.
  • UTR GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 131)
  • PCT/US2016/058314 PCT/US2016/058310, PCT/US2016/058321, PCT/US2016/058297, PCT/US2016/058319, and PCT/US2016/058314 are incorporated herein by reference.

Abstract

La divulgation concerne des vaccins à base d'acide ribonucléique (ARN) ainsi que des méthodes d'utilisation de ces vaccins et des compositions comprenant lesdits vaccins. Les vaccins à ARN encodent des domaines et des sous-unités de coronavirus.
EP21709270.9A 2020-02-07 2021-02-06 Vaccins à domaine arnm anti sars-cov-2 Pending EP4100052A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062971825P 2020-02-07 2020-02-07
US202063016175P 2020-04-27 2020-04-27
US202063044330P 2020-06-25 2020-06-25
US202063063137P 2020-08-07 2020-08-07
PCT/US2021/016979 WO2021159040A2 (fr) 2020-02-07 2021-02-06 Vaccins à domaine arnm anti sars-cov-2

Publications (1)

Publication Number Publication Date
EP4100052A2 true EP4100052A2 (fr) 2022-12-14

Family

ID=74845093

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21709270.9A Pending EP4100052A2 (fr) 2020-02-07 2021-02-06 Vaccins à domaine arnm anti sars-cov-2

Country Status (11)

Country Link
US (1) US20230346914A1 (fr)
EP (1) EP4100052A2 (fr)
JP (3) JP7438604B2 (fr)
KR (1) KR20220140528A (fr)
CN (1) CN115551545A (fr)
AU (1) AU2021215938A1 (fr)
BR (1) BR112022015565A2 (fr)
CA (1) CA3170150A1 (fr)
IL (1) IL295377A (fr)
MX (1) MX2022009707A (fr)
WO (1) WO2021159040A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031232A1 (fr) 2015-08-17 2017-02-23 Modernatx, Inc. Procédés de préparation de particules et compositions associées
EP4011451A1 (fr) 2015-10-22 2022-06-15 ModernaTX, Inc. Vaccins contre le virus respiratoire
EP3364981A4 (fr) 2015-10-22 2019-08-07 ModernaTX, Inc. Vaccin contre le cytomégalovirus humain
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3668977A4 (fr) 2017-08-18 2021-04-21 Modernatx, Inc. Procédés analytiques par hplc
WO2019036682A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Variants d'arn polymérase
EP3668979A4 (fr) 2017-08-18 2021-06-02 Modernatx, Inc. Procédés pour analyse par clhp
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
GB2594365B (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
CN113684219B (zh) * 2020-05-18 2022-12-23 康希诺(上海)生物科技有限公司 mRNA或mRNA组合物及其制备方法和应用
US20230322863A1 (en) * 2020-08-24 2023-10-12 Phylex Biosciences, Inc. Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
EP4277655A1 (fr) * 2021-01-15 2023-11-22 ModernaTX, Inc. Vaccins anti-coronavirus à base de souche variante
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022197624A1 (fr) * 2021-03-15 2022-09-22 Modernatx, Inc. Utilisation thérapeutique de vaccins à domaine arnm de sars-cov-2
AU2022270658A1 (en) 2021-05-04 2023-11-16 BioNTech SE Technologies for early detection of variants of interest
GB2623728A (en) * 2021-08-15 2024-04-24 R Burton Dennis Undirected mutated MRNA vaccine
WO2023019309A1 (fr) * 2021-08-17 2023-02-23 Monash University Compositions vaccinales
WO2023026170A1 (fr) * 2021-08-24 2023-03-02 Victoria Link Limited Polypeptide de fusion
WO2023034991A1 (fr) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Formulations de vaccin à arnm et leurs procédés d'utilisation
CN113527522B (zh) * 2021-09-13 2021-12-21 深圳市瑞吉生物科技有限公司 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗
CN116064598B (zh) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023060483A1 (fr) * 2021-10-13 2023-04-20 清华大学 Immunoconjugué polypeptide-rbd et son utilisation
WO2023064993A1 (fr) * 2021-10-21 2023-04-27 The University Of Melbourne Polypeptides chimériques de spicule de bêta-coronavirus
CA3235180A1 (fr) 2021-10-21 2023-04-27 BioNTech SE Vaccin contre le coronavirus
WO2023092069A1 (fr) * 2021-11-18 2023-05-25 Modernatx, Inc. Vaccins à domaine arnm de sars-cov-2 et méthodes d'utilisation
WO2023096990A1 (fr) * 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
TW202333780A (zh) 2021-11-29 2023-09-01 德商拜恩技術股份公司 冠狀病毒疫苗
IL288634A (en) * 2021-12-02 2023-07-01 Yeda Res & Dev Improving the translation and protein secretion efficiency of mRNA vaccines
WO2023113094A1 (fr) * 2021-12-16 2023-06-22 주식회사 씨티씨백 Composition de vaccin contre la covid-19 présentant une immunogénicité renforcée
WO2023125974A1 (fr) * 2021-12-31 2023-07-06 广州国家实验室 Vaccin à arnm
WO2023142283A1 (fr) 2022-01-27 2023-08-03 深圳市瑞吉生物科技有限公司 Vaccin à arnm contre le sras-cov-2, son procédé de préparation et son utilisation
EP4242308A1 (fr) * 2022-01-27 2023-09-13 Shenzhen Rhegen Biotechnology Co., Ltd. Vaccin à arnm contre le sras-cov-2, son procédé de préparation et son utilisation
WO2023143600A1 (fr) * 2022-01-30 2023-08-03 康希诺生物股份公司 Nouveau lipide ionisable pour l'administration d'acide nucléique, composition de lnp et vaccin associés
CN114213509B (zh) * 2022-02-22 2022-06-10 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗及其用途
CN116726162A (zh) * 2022-03-11 2023-09-12 病毒与疫苗研究中心有限公司 用于呼吸道病毒性疾病的疫苗加强组合物
KR20230144421A (ko) * 2022-04-07 2023-10-16 엠큐렉스 주식회사 사스-코로나바이러스 2 감염증에 대한 rna 백신
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024086575A1 (fr) 2022-10-17 2024-04-25 BioNTech SE Combinaison de vaccins contre une infection au coronavirus, une infection grippale et/ou une infection à vrs
CN117003835A (zh) * 2023-03-17 2023-11-07 成都威斯克生物医药有限公司 抗SARS-CoV-2奥密克戎突变株XBB及其亚型感染的蛋白及疫苗

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP2305699B1 (fr) 2001-06-05 2014-08-13 CureVac GmbH ARNm stabilisée avec un contenu augmenté en G/C et optimisée pour la translation dans ses zones codées pour la vaccination contre la trypanosomiase, la leishmaniose et la toxoplasmose
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK3156414T3 (da) 2007-09-26 2020-03-09 Intrexon Corp Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
CA2904904A1 (fr) 2007-12-11 2009-06-18 The Scripps Research Institute Compositions et procedes concernant des elements activateurs de traduction de l'arnm
CN102695525B (zh) 2009-07-31 2016-01-20 埃泽瑞斯公司 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
WO2014071963A1 (fr) 2012-11-09 2014-05-15 Biontech Ag Procédé pour l'expression d'arn cellulaire
LT2970456T (lt) 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
WO2015024667A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Procédé pour augmenter l'expression de protéines codées par l'arn
CA2925021A1 (fr) 2013-11-01 2015-05-07 Curevac Ag Arn modifie a proprietes immunostimulantes reduites
BR112016014462A2 (pt) 2013-12-30 2017-10-24 Curevac Ag moléculas de ácido nucleico artificiais
WO2015101415A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Molécules d'acides nucléiques artificielles
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
EP4011451A1 (fr) 2015-10-22 2022-06-15 ModernaTX, Inc. Vaccins contre le virus respiratoire
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
US11141476B2 (en) * 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
WO2018151816A1 (fr) 2017-02-16 2018-08-23 Modernatx, Inc. Compositions immunogènes très puissantes
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2019036682A1 (fr) 2017-08-18 2019-02-21 Modernatx, Inc. Variants d'arn polymérase

Also Published As

Publication number Publication date
AU2021215938A1 (en) 2022-09-01
WO2021159040A9 (fr) 2021-11-25
JP7438604B2 (ja) 2024-02-27
CN115551545A (zh) 2022-12-30
US20230346914A1 (en) 2023-11-02
MX2022009707A (es) 2022-09-07
JP7443608B2 (ja) 2024-03-05
JP2024050973A (ja) 2024-04-10
KR20220140528A (ko) 2022-10-18
JP2023153256A (ja) 2023-10-17
JP2023513544A (ja) 2023-03-31
IL295377A (en) 2022-10-01
WO2021159040A3 (fr) 2021-11-04
BR112022015565A2 (pt) 2022-09-27
WO2021159040A2 (fr) 2021-08-12
CA3170150A1 (fr) 2021-08-12

Similar Documents

Publication Publication Date Title
US20230346914A1 (en) Sars-cov-2 mrna domain vaccines
US20230108894A1 (en) Coronavirus rna vaccines
US20230355743A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
US20240139309A1 (en) Variant strain-based coronavirus vaccines
US20240100151A1 (en) Variant strain-based coronavirus vaccines
WO2021222304A1 (fr) Vaccins à arn contre le sars-cov-2
WO2021159130A2 (fr) Vaccins a arn de coronavirus et procédés d'utilisation
WO2021211343A1 (fr) Vaccins à arnm contre le virus zika
AU2022258463A9 (en) Influenza-coronavirus combination vaccines
WO2023283642A2 (fr) Vaccins concatémères à coronavirus pan-humain
EP4355761A1 (fr) Vaccins à arnm codant pour des protéines de spicule de coronavirus flexibles
EP4355891A1 (fr) Vaccins contre les variants de glycosylation de coronavirus
WO2023283645A1 (fr) Vaccins à domaine de coronavirus pan-humain
WO2023283651A1 (fr) Vaccins pan-coronavirus humains
WO2023092069A1 (fr) Vaccins à domaine arnm de sars-cov-2 et méthodes d'utilisation
AU2022237382A1 (en) Therapeutic use of sars-cov-2 mrna domain vaccines
TW202217000A (zh) Ｓａｒｓ—ｃｏｖ—２ ｍｒｎａ結構域疫苗

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082101

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS